## Enrico Bertini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2048579/publications.pdf

Version: 2024-02-01

2215 5255 42,990 727 99 165 citations h-index g-index papers 759 759 759 36015 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Refining the mutational spectrum and gene–phenotype correlates in pontocerebellar hypoplasia: results of a multicentric study. Journal of Medical Genetics, 2022, 59, 399-409.	3.2	13
2	PIGQ-Related Glycophosphatidylinositol Deficiency Associated with Nonprogressive Congenital Ataxia. Cerebellum, 2022, 21, 525-530.	2.5	2
3	Personalized profiles of antioxidant signaling pathway in patients with tuberculosis. Journal of Microbiology, Immunology and Infection, 2022, 55, 405-412.	3.1	3
4	<i>SUFU</i> haploinsufficiency causes a recognisable neurodevelopmental phenotype at the mild end of the Joubert syndrome spectrum. Journal of Medical Genetics, 2022, 59, 888-894.	3.2	19
5	Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1136-e1147.	3.6	15
6	Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscular Disorders, 2022, 32, 36-42.	0.6	13
7	Clinical variability at the mild end of <i>BRAT1</i> â€related spectrum: Evidence from two families with genotype–phenotype discordance. Human Mutation, 2022, 43, 67-73.	2.5	9
8	Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. Journal of Comparative Effectiveness Research, 2022, 11, 139-155.	1.4	29
9	A case of spastic paraplegia type $11$ mimicking a GM2-gangliosidosis. Neurological Sciences, 2022, 43, 2849-2852.	1.9	0
10	Movement disorders in MCT8 deficiency/Allan-Herndon-Dudley Syndrome. Molecular Genetics and Metabolism, 2022, 135, 109-113.	1.1	17
11	Toward the inÂvitro understanding of iPSC nucleoskeletal and cytoskeletal biology, and their relevance for organoid development. , 2022, , 137-150.		O
12	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	10.2	89
13	Body mass index in type 2 spinal muscular atrophy: a longitudinal study. European Journal of Pediatrics, 2022, , 1.	2.7	2
14	Cerebellar Agenesis and Bilateral Polimicrogyria Associated with Rare Variants of CUB and Sushi Multiple Domains 1 Gene (CSMD1): A Longitudinal Neuropsychological and Neuroradiological Case Study. International Journal of Environmental Research and Public Health, 2022, 19, 1224.	2.6	0
15	Neurological and Neuroimaging Features of CYB5R3-Related Recessive Hereditary Methemoglobinemia Type II. Brain Sciences, 2022, 12, 182.	2.3	4
16	Therapy Trial Design in Vanishing White Matter. Neurology: Genetics, 2022, 8, e657.	1.9	12
17	Upper Body Physical Rehabilitation for Children with Ataxia through IMU-Based Exergame. Journal of Clinical Medicine, 2022, 11, 1065.	2.4	7
18	Nusinersen efficacy data for 24â€month in type 2 and 3 spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 404-409.	3.7	22

#	Article	IF	Citations
19	Modeling PCDH19-CE: From 2D Stem Cell Model to 3D Brain Organoids. International Journal of Molecular Sciences, 2022, 23, 3506.	4.1	1
20	Novel <i>SEPSECS</i> Pathogenic Variants Featuring Unusual Phenotype of Complex Movement Disorder With Thin Corpus Callosum. Neurology: Genetics, 2022, 8, e661.	1.9	0
21	Clinical-Genetic Features Influencing Disability in Spastic Paraplegia Type 4. Neurology: Genetics, 2022, 8, e664.	1.9	9
22	Clinical and Genetic Aspects of Phelan–McDermid Syndrome: An Interdisciplinary Approach to Management. Genes, 2022, 13, 504.	2.4	9
23	A novel homozygous variant in <scp><i>COX5A</i></scp> causes an attenuated phenotype with failure to thrive, lactic acidosis, hypoglycemia, and short stature. Clinical Genetics, 2022, 102, 56-60.	2.0	3
24	Response to: Phenotypic heterogeneity of Leigh syndrome due to <i>NDUFA12</i> variants is multicausal. Human Mutation, 2022, 43, 99-100.	2.5	0
25	Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study. Acta Neuropathologica Communications, 2022, 10, 54.	5.2	3
26	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	3 <b>.</b> 6	2
27	"Atypical―Krabbe disease in two siblings harboring biallelic GALC mutations including a deep intronic variant. European Journal of Human Genetics, 2022, , .	2.8	4
28	Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain, 2022, 145, 3383-3390.	7.6	3
29	Superior Cerebellar Atrophy: An Imaging Clue to Diagnose ITPR1-Related Disorders. International Journal of Molecular Sciences, 2022, 23, 6723.	4.1	4
30	New Insights into the Neurodegeneration Mechanisms Underlying Riboflavin Transporter Deficiency (RTD): Involvement of Energy Dysmetabolism and Cytoskeletal Derangement. Biomedicines, 2022, 10, 1329.	3.2	5
31	Heterozygous <i>KIF1A</i> variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. Journal of Medical Genetics, 2021, 58, 475-483.	3.2	21
32	Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen. European Journal of Neurology, 2021, 28, 602-608.	3.3	9
33	Clinical phenotypes of infantile onset CACNA1A-related disorder. European Journal of Paediatric Neurology, 2021, 30, 144-154.	1.6	13
34	Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology, 2021, 96, e587-e599.	1.1	36
35	Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores. Neuromuscular Disorders, 2021, 31, 139-148.	0.6	4
36	Clinical and radiological profile of patients with spinal muscular atrophy type 4. European Journal of Neurology, 2021, 28, 609-619.	3.3	23

#	Article	IF	CITATIONS
37	Friedreich ataxia in COVID-19 time: current impact and future possibilities. Cerebellum and Ataxias, 2021, 8, 4.	1.9	8
38	Type I SMA "new natural history― longâ€term data in nusinersenâ€treated patients. Annals of Clinical and Translational Neurology, 2021, 8, 548-557.	3.7	35
39	The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure. Neuromuscular Disorders, 2021, 31, 409-418.	0.6	7
40	Nuclear Factor Erythroid 2-Related Factor 2 Activation Might Mitigate Clinical Symptoms in Friedreich's Ataxia: Clues of an "Out-Brain Origin―of the Disease From a Family Study. Frontiers in Neuroscience, 2021, 15, 638810.	2.8	5
41	Altered cytoskeletal arrangement in induced pluripotent stem cells and motor neurons from patients with riboflavin transporter deficiency. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	5
42	Mitochondrial Dynamics: Molecular Mechanisms, Related Primary Mitochondrial Disorders and Therapeutic Approaches. Genes, 2021, 12, 247.	2.4	25
43	Novel <i>NDUFA12</i> variants are associated with isolated complex I defect and variable clinical manifestation. Human Mutation, 2021, 42, 699-710.	2.5	12
44	CASK related disorder: Epilepsy and developmental outcome. European Journal of Paediatric Neurology, 2021, 31, 61-69.	1.6	7
45	Predictive fat mass equations for spinal muscular atrophy type I children: Development and internal validation. Clinical Nutrition, 2021, 40, 1578-1587.	5.0	3
46	Challenges and resources in adult life with Joubert syndrome: issues from an international classification of functioning (ICF) perspective. Disability and Rehabilitation, 2021, , 1-8.	1.8	1
47	Biâ€allelic <i>KARS1</i> ) pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease. Human Mutation, 2021, 42, 745-761.	2.5	7
48	Movement Disorders in Children with a Mitochondrial Disease: A Cross-Sectional Survey from the Nationwide Italian Collaborative Network of Mitochondrial Diseases. Journal of Clinical Medicine, 2021, 10, 2063.	2.4	8
49	Biallelic mutations in <i>RNF220</i> cause laminopathies featuring leukodystrophy, ataxia and deafness. Brain, 2021, 144, 3020-3035.	7.6	11
50	Dissecting the Role of PCDH19 in Clustering Epilepsy by Exploiting Patient-Specific Models of Neurogenesis. Journal of Clinical Medicine, 2021, 10, 2754.	2.4	13
51	Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1622-1634.	3.7	27
52	Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscular Disorders, 2021, 31, 574-582.	0.6	94
53	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	2.4	15
54	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	2.5	6

#	Article	IF	Citations
55	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.6	O
56	Circadian Genes as Exploratory Biomarkers in DMD: Results From Both the mdx Mouse Model and Patients. Frontiers in Physiology, 2021, 12, 678974.	2.8	1
57	Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen. Neuromuscular Disorders, 2021, 31, 596-602.	0.6	29
58	Expanded phenotype of AARS1-related white matter disease. Genetics in Medicine, 2021, 23, 2352-2359.	2.4	8
59	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle and Nerve, 2021, 64, 552-559.	2.2	18
60	Ageâ€related sensory neuropathy in patients with spinal muscular atrophy type 1. Muscle and Nerve, 2021, 64, 599-603.	2.2	3
61	Growth patterns in children with spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 375.	2.7	19
62	SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples. ELife, 2021, 10, .	6.0	13
63	Broadening the spectrum phenotype of TBCE-related neuron neurodegeneration. Brain and Development, 2021, 43, 939-944.	1.1	0
64	Expanding the Clinical and Mutational Spectrum of the PLP1-Related Hypomyelination of Early Myelinated Structures (HEMS). Brain Sciences, 2021, 11, 93.	2.3	3
65	Clinical, imaging, biochemical and molecular features in Leigh syndrome: a study from the Italian network of mitochondrial diseases. Orphanet Journal of Rare Diseases, 2021, 16, 413.	2.7	16
66	Myocardial and Arrhythmic Spectrum of Neuromuscular Disorders in Children. Biomolecules, 2021, 11, 1578.	4.0	5
67	Artificial Intelligence for Dysarthria Assessment in Children With Ataxia: A Hierarchical Approach. IEEE Access, 2021, 9, 166720-166735.	4.2	4
68	Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases. International Journal of Molecular Sciences, 2021, 22, 13674.	4.1	13
69	Impaired urinary concentration ability is a sensitive predictor of renal disease progression in Joubert syndrome. Nephrology Dialysis Transplantation, 2020, 35, 1195-1202.	0.7	15
70	Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy. Cerebellum, 2020, 19, 126-130.	2.5	12
71	Hereditary spastic paraplegia is a novel phenotype for germline de novo <i>ATP1A1</i> mutation. Clinical Genetics, 2020, 97, 521-526.	2.0	14
72	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscular Disorders, 2020, 30, 93-103.	0.6	55

#	Article	IF	CITATIONS
73	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. Movement Disorders, 2020, 35, 180-184.	3.9	66
74	Genome sequencing in persistently unsolved white matter disorders. Annals of Clinical and Translational Neurology, 2020, 7, 144-152.	3.7	26
75	<i>RARS1</i> å€related hypomyelinating leukodystrophy: Expanding the spectrum. Annals of Clinical and Translational Neurology, 2020, 7, 83-93.	3.7	18
76	Development of SaraHome: A novel, well-accepted, technology-based assessment tool for patients with ataxia. Computer Methods and Programs in Biomedicine, 2020, 188, 105257.	4.7	21
77	Mitochondrial epilepsy: a cross-sectional nationwide Italian survey. Neurogenetics, 2020, 21, 87-96.	1.4	14
78	SMA – THERAPY. Neuromuscular Disorders, 2020, 30, S123-S124.	0.6	6
79	<i><scp>PPP1R21</scp>â€</i> related syndromic intellectual disability: Report of an adult patient and review. American Journal of Medical Genetics, Part A, 2020, 182, 3014-3022.	1.2	8
80	Long-Term Outcome of LVAD in Duchenne Population with End Stage Cardiomyopathy. Journal of Heart and Lung Transplantation, 2020, 39, S219-S220.	0.6	0
81	Microtubule Dysfunction: A Common Feature of Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 7354.	4.1	63
82	A Recurrent Pathogenic Variant of INPP5K Underlies Autosomal Recessive Congenital Muscular Dystrophy With Cataracts and Intellectual Disability: Evidence for a Founder Effect in Southern Italy. Frontiers in Genetics, 2020, 11, 565868.	2.3	8
83	Spatio-temporal parameters of ataxia gait dataset obtained with the Kinect. Data in Brief, 2020, 32, 106307.	1.0	10
84	Antioxidant Amelioration of Riboflavin Transporter Deficiency in Motoneurons Derived from Patient-Specific Induced Pluripotent Stem Cells. International Journal of Molecular Sciences, 2020, 21, 7402.	4.1	8
85	Validation of low-cost system for gait assessment in children with ataxia. Computer Methods and Programs in Biomedicine, 2020, 196, 105705.	4.7	17
86	Aicardi–GoutiÔres Syndrome Type 2: A Report on Two Cases with Different Phenotypes Caused by RNASEH2B Gene Mutations. Journal of Pediatric Neurology, 2020, 18, 206-209.	0.2	0
87	Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 594-605.	11.4	50
88	Response to "Autosomal recessive axonal neuropathy caused by HINT1 mutation: New association of a psychiatric disorder to the neurological phenotype― Neuromuscular Disorders, 2020, 30, 265-266.	0.6	4
89	Ferroptosis in Friedreich's Ataxia: A Metal-Induced Neurodegenerative Disease. Biomolecules, 2020, 10, 1551.	4.0	21
90	Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment. Genetics in Medicine, 2020, 22, 1851-1862.	2.4	30

#	Article	IF	CITATIONS
91	Cardiovascular Involvement in Pediatric Laminopathies. Report of Six Patients and Literature Revision. Frontiers in Pediatrics, 2020, 8, 374.	1.9	9
92	Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscular Disorders, 2020, 30, 756-764.	0.6	25
93	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
94	Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-19.	4.0	13
95	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp> . Annals of Neurology, 2020, 88, 1109-1117.	5.3	34
96	The clinical, histologic, and genotypic spectrum of <i>SEPN1</i> -related myopathy. Neurology, 2020, 95, e1512-e1527.	1.1	44
97	Mitochondrial Abnormalities in Induced Pluripotent Stem Cells-Derived Motor Neurons from Patients with Riboflavin Transporter Deficiency. Antioxidants, 2020, 9, 1252.	5.1	11
98	Movement disorders in ADAR1 disease: Insights from a comprehensive cohort. Parkinsonism and Related Disorders, 2020, 79, 100-104.	2.2	6
99	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.6	15
100	Oxidative Stress in DNA Repeat Expansion Disorders: A Focus on NRF2 Signaling Involvement. Biomolecules, 2020, 10, 702.	4.0	17
101	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.6	40
102	Age and sex prevalence estimate of Joubert syndrome in Italy. Neurology, 2020, 94, e797-e801.	1.1	26
103	Predictive energy equations for spinal muscular atrophy type I children. American Journal of Clinical Nutrition, 2020, 111, 983-996.	4.7	8
104	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	2.3	49
105	Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?. PLoS ONE, 2020, 15, e0230677.	2.5	38
106	Co-occurrence of mutations in KIF7 and KIAA0556 in Joubert syndrome with ocular coloboma, pituitary malformation and growth hormone deficiency: a case report and literature review. BMC Pediatrics, 2020, 20, 120.	1.7	12
107	Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Frontiers in Genetics, 2020, 11, 605.	2.3	9
108	The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich's Ataxia. International Journal of Molecular Sciences, 2020, 21, 916.	4.1	27

#	Article	IF	CITATIONS
109	Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy TreatedÂwith Nusinersen. Journal of Pediatrics, 2020, 219, 223-228.e4.	1.8	51
110	TUBB Variants Underlying Different Phenotypes Result in Altered Vesicle Trafficking and Microtubule Dynamics. International Journal of Molecular Sciences, 2020, 21, 1385.	4.1	20
111	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	3.7	36
112	A wearable video-oculography based evaluation of saccades and respective clinical correlates in patients with early onset ataxia. Journal of Neuroscience Methods, 2020, 338, 108697.	2.5	3
113	Clinicoâ€Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp> â€Ataxia: A Multicenter Study of 59 Patients. Annals of Neurology, 2020, 88, 251-263.	5.3	52
114	A homozygous MRPL24 mutation causes a complex movement disorder and affects the mitoribosome assembly. Neurobiology of Disease, 2020, 141, 104880.	4.4	29
115	Clinico-Genetic, Imaging and Molecular Delineation of COQ8A-Ataxia: A Multicenter Study of 59 Patients. , 2020, 88, 251.		1
116	HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscleâ€resident mesenchymal cells. EMBO Reports, 2020, 21, e50863.	4.5	45
117	Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias. International Journal of Molecular Sciences, 2020, 21, 3603.	4.1	36
118	A clinical diagnostic algorithm for early onset cerebellar ataxia. European Journal of Paediatric Neurology, 2019, 23, 692-706.	1.6	37
119	Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich's Ataxia Neural Stem Cells. Frontiers in Cellular Neuroscience, 2019, 13, 356.	3.7	36
120	Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 695-706.	11.4	77
121	Defining the clinical-genetic and neuroradiological features in SPG54: description of eight additional cases and nine novel DDHD2 variants. Journal of Neurology, 2019, 266, 2657-2664.	3.6	19
122	Observations from a nationwide vigilance program in medical care for spinal muscular atrophy patients in Chile. Arquivos De Neuro-Psiquiatria, 2019, 77, 470-477.	0.8	6
123	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. Parkinsonism and Related Disorders, 2019, 68, 8-16.	2.2	25
124	â€~Amish Nemaline Myopathy' in 2 Italian siblings harbouring a novel homozygous mutation in Troponin-I gene. Neuromuscular Disorders, 2019, 29, 766-770.	0.6	13
125	Evaluation of gait in Duchenne Muscular Dystrophy: Relation of 3D gait analysis to clinical assessment. Neuromuscular Disorders, 2019, 29, 920-929.	0.6	14
126	Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs. International Journal of Molecular Sciences, 2019, 20, 5211.	4.1	45

#	Article	IF	CITATIONS
127	Development of an academic disease registry for spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 794-799.	0.6	29
128	Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 857-862.	0.6	23
129	Corticospinal tract damage in HHH syndrome: a metabolic cause of hereditary spastic paraplegia. Orphanet Journal of Rare Diseases, 2019, 14, 208.	2.7	12
130	Aberrant Function of the C-Terminal Tail of HIST1H1E Accelerates Cellular Senescence and Causes Premature Aging. American Journal of Human Genetics, 2019, 105, 493-508.	6.2	48
131	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.6	401
132	Diagnosis of â€~possible' mitochondrial disease: an existential crisis. Journal of Medical Genetics, 2019, 56, 123-130.	3.2	42
133	Heart rate reduction strategy using ivabradine in end-stage Duchenne cardiomyopathy. International Journal of Cardiology, 2019, 280, 99-103.	1.7	17
134	Clinical, radiological, and genetic characteristics of 16 patients with <i>ACO2</i> gene defects: Delineation of an emerging neurometabolic syndrome. Journal of Inherited Metabolic Disease, 2019, 42, 264-275.	3.6	18
135	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	5.3	83
136	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	2.5	47
137	Molecular Genetics and Interferon Signature in the Italian Aicardi GoutiÃ'res Syndrome Cohort: Report of 12 New Cases and Literature Review. Journal of Clinical Medicine, 2019, 8, 750.	2.4	29
138	Heterozygous missense variants of <i>SPTBN2</i> are a frequent cause of congenital cerebellar ataxia. Clinical Genetics, 2019, 96, 169-175.	2.0	27
139	Response to Jardim and colleagues regarding comments on †Natural history of a cohort of <i><i><scp>ABCD</scp>1</i> variant female carriers'. European Journal of Neurology, 2019, 26, e77.</i>	3.3	0
140	Mutations in <i>ELAC2</i> sassociated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3′â€end processing. Human Mutation, 2019, 40, 1731-1748.	2.5	31
141	Mitochondrial Neurodegenerative Disorders II: Ataxia, Dystonia and Leukodystrophies. , 2019, , 241-256.		1
142	Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE, 2019, 14, e0214250.	2.5	59
143	An unusual case of late-infantile onset Krabbe disease with selective bilateralÂcorticospinal tract involvement, peripheral demyelinating neuropathy, and mild phenotype. Acta Neurologica Belgica, 2019, 119, 619-620.	1.1	1
144	Biallelic Variants in the Nuclear Pore Complex Protein NUP93 Are Associated with Non-progressive Congenital Ataxia. Cerebellum, 2019, 18, 422-432.	2.5	10

#	Article	IF	CITATIONS
145	Clinical-genetic features and peculiar muscle histopathology in infantile (i>DNM1L  mitochondrial epileptic encephalopathy. Human Mutation, 2019, 40, 601-618.	2.5	31
146	Cardiac and Neuromuscular Features of Patients With <i>LMNA</i> -Related Cardiomyopathy. Annals of Internal Medicine, 2019, 171, 458.	3.9	33
147	One-year outcome of coenzyme Q10 supplementation in ADCK3 ataxia (ARCA2). Cerebellum and Ataxias, 2019, 6, 15.	1.9	15
148	Diagnostic Yield of a Targeted Next-Generation Sequencing Gene Panel for Pediatric-Onset Movement Disorders: A 3-Year Cohort Study. Frontiers in Genetics, 2019, 10, 1026.	2.3	33
149	Primary muscle involvement in a 15â€yearâ€old girl with the recurrent homozygous c.362dupC variant in <i>FKBP14</i> . American Journal of Medical Genetics, Part A, 2019, 179, 317-321.	1.2	3
150	A novel KCTD17 mutation is associated with childhood early-onset hyperkinetic movement disorder. Parkinsonism and Related Disorders, 2019, 61, 4-6.	2.2	22
151	Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurological Sciences, 2019, 40, 457-468.	1.9	24
152	APOPT $1/$ COA 8 assists COX assembly and is oppositely regulated by UPS and ROS. EMBO Molecular Medicine, 2019, $11$ , .	6.9	19
153	SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia. European Journal of Paediatric Neurology, 2019, 23, 329-332.	1.6	11
154	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism and Related Disorders, 2019, 61, 19-25.	2.2	64
155	Natural history of a cohort of <i><scp>ABCD</scp>1</i> variant female carriers. European Journal of Neurology, 2019, 26, 326-332.	3.3	19
156	Neonatal Hypotonia., 2019, , 223-233.		0
157	SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder. Journal of Clinical Investigation, 2019, 130, 108-125.	8.2	65
158	Clinical spectrum of POLR3-related leukodystrophy caused by biallelic <i>POLR1C</i> pathogenic variants. Neurology: Genetics, 2019, 5, e369.	1.9	38
159	Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clinical Neurology and Neurosurgery, 2018, 168, 60-63.	1.4	9
160	Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 2018, 28, 103-115.	0.6	584
161	Novel Homozygous KCNJ10 Mutation in a Patient with Non-syndromic Early-Onset Cerebellar Ataxia. Cerebellum, 2018, 17, 499-503.	2.5	10
162	A V1143F mutation in the neuronal-enriched isoform 2 of the PMCA pump is linked with ataxia. Neurobiology of Disease, 2018, 115, 157-166.	4.4	15

#	Article	IF	CITATIONS
163	Clinical and imaging hallmarks of the <i>MYH7</i> å€related myopathy with severe axial involvement. Muscle and Nerve, 2018, 58, 224-234.	2.2	14
164	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1― written by pechmann and colleagues― European Journal of Paediatric Neurology, 2018, 22, 729-731.	1.6	5
165	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. Brain and Development, 2018, 40, 433-438.	1.1	23
166	Serum uric acid in Friedreich Ataxia. Clinical Biochemistry, 2018, 54, 139-141.	1.9	7
167	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. Cerebellum, 2018, 17, 489-493.	2.5	24
168	Deep intronic variation in splicing regulatory element of the ERCC8 gene associated with severe but long-term survival Cockayne syndrome. European Journal of Human Genetics, 2018, 26, 527-536.	2.8	7
169	A prospective natural history study of type 1 spinal muscular atrophy. Nature Reviews Neurology, 2018, 14, 197-198.	10.1	4
170	Neuromyopathy with congenital cataracts and glaucoma: a distinct syndrome caused by POLG variants. European Journal of Human Genetics, 2018, 26, 367-373.	2.8	3
171	Clinical, biochemical, and genetic features associated with <i>VARS2</i> -related mitochondrial disease. Human Mutation, 2018, 39, 563-578.	2.5	22
172	Expanding the histopathological spectrum of <i>CFL2</i> a€related myopathies. Clinical Genetics, 2018, 93, 1234-1239.	2.0	11
173	The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes. Neurogenetics, 2018, 19, 111-121.	1.4	52
174	Defective kinesin binding of TUBB2A causes progressive spastic ataxia syndrome resembling sacsinopathy. Human Molecular Genetics, 2018, 27, 1892-1904.	2.9	29
175	Compound heterozygous missense and deep intronic variants in NDUFAF6 unraveled by exome sequencing and mRNA analysis. Journal of Human Genetics, 2018, 63, 563-568.	2.3	15
176	MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77.	1.9	55
177	Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 2018, 28, 197-207.	0.6	421
178	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 4-15.	0.6	102
179	Longitudinal gait assessment in a stiff person syndrome. International Journal of Rehabilitation Research, 2018, 41, 377-379.	1.3	6
180	Defining the electroclinical phenotype and outcome of PCDH19â€related epilepsy: A multicenter study. Epilepsia, 2018, 59, 2260-2271.	5.1	39

#	Article	IF	Citations
181	Non-invasive Focal Mechanical Vibrations Delivered by Wearable Devices: An Open-Label Pilot Study in Childhood Ataxia. Frontiers in Neurology, 2018, 9, 849.	2.4	10
182	Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. Orphanet Journal of Rare Diseases, 2018, 13, 170.	2.7	26
183	ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe–4S] proteins. Human Molecular Genetics, 2018, 27, 3650-3650.	2.9	6
184	Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients. Genes, 2018, 9, 524.	2.4	7
185	Core-rod myopathy due to a novel mutation in BTB/POZ domain of KBTBD13 manifesting as late onset LGMD. Acta Neuropathologica Communications, 2018, 6, 94.	5.2	12
186	ISCA1 mutation in a patient with infantile-onset leukodystrophy causes defects in mitochondrial [4Fe–4S] proteins. Human Molecular Genetics, 2018, 27, 2739-2754.	2.9	25
187	Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS ONE, 2018, 13, e0199223.	2.5	45
188	Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphiâ€based international workshop. Journal of Inherited Metabolic Disease, 2018, 41, 1267-1273.	3.6	24
189	An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology, 2018, 91, e696-e703.	1.1	24
190	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscular Disorders, 2018, 28, 582-585.	0.6	67
191	Nonprogressive congenital ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 91-103.	1.8	32
192	X-linked ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 175-189.	1.8	17
193	A novel mutation in <i><scp>NDUFB11</scp></i> unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia. Clinical Genetics, 2017, 91, 441-447.	2.0	24
194	Mutations in the <scp>IRBIT</scp> domain of <i><scp>ITPR1</scp></i> are a frequent cause of autosomal dominant nonprogressive congenital ataxia. Clinical Genetics, 2017, 91, 86-91.	2.0	30
195	Blood malignancies presenting with mutations at equivalent residues in RUNX1–2 suggest a common leukemogenic pathway. Leukemia and Lymphoma, 2017, 58, 2002-2004.	1.3	4
196	Novel mutation in mitochondrial Elongation Factor EF-Tu associated to dysplastic leukoencephalopathy and defective mitochondrial DNA translation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 961-967.	3.8	12
197	Microcephaly, intractable seizures and developmental delay caused by biallelic variants in ⟨i⟩⟨scp⟩⟨li⟩: further delineation of a new chaperoneâ€mediated tubulinopathy. Clinical Genetics, 2017, 91, 725-738.	2.0	25
198	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscular Disorders, 2017, 27, 447-451.	0.6	42

#	Article	IF	Citations
199	218th ENMC International Workshop:. Neuromuscular Disorders, 2017, 27, 596-605.	0.6	49
200	De novo p.T362R mutation in MORC2 causes early onset cerebellar ataxia, axonal polyneuropathy and nocturnal hypoventilation. Brain, 2017, 140, e34-e34.	7.6	17
201	Muscle MRI in neutral lipid storage disease (NLSD). Journal of Neurology, 2017, 264, 1334-1342.	3.6	15
202	Reduced steroidogenesis in patients with <scp>PCDH</scp> 19â€female limited epilepsy. Epilepsia, 2017, 58, e91-e95.	5.1	40
203	Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway. Human Molecular Genetics, 2017, 26, 2781-2790.	2.9	71
204	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	10.2	95
205	Novel mutations in <i><scp>KARS</scp></i> cause hypertrophic cardiomyopathy and combined mitochondrial respiratory chain defect. Clinical Genetics, 2017, 91, 918-923.	2.0	27
206	Insights from genotype–phenotype correlations by novel SPEG mutations causing centronuclear myopathy. Neuromuscular Disorders, 2017, 27, 836-842.	0.6	27
207	Expanding the clinical phenotype of CAPN1- associated mutations: A new case with congenital-onset pure spastic paraplegia. Journal of the Neurological Sciences, 2017, 378, 210-212.	0.6	21
208	Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown–Vialetto disease that is partially rescued by riboflavin. Scientific Reports, 2017, 7, 46271.	3.3	22
209	Missense mutations of CACNA1A are a frequent cause of autosomal dominant nonprogressive congenital ataxia. European Journal of Paediatric Neurology, 2017, 21, 450-456.	1.6	37
210	A novel gainâ€ofâ€function mutation in <i>ORAI1</i> causes lateâ€onset tubular aggregate myopathy and congenital miosis. Clinical Genetics, 2017, 91, 780-786.	2.0	50
211	Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience. Neuromuscular Disorders, 2017, 27, 1084-1086.	0.6	38
212	Hypomorphic Recessive Variants in SUFU Impair the Sonic Hedgehog Pathway and Cause Joubert Syndrome with Cranio-facial and Skeletal Defects. American Journal of Human Genetics, 2017, 101, 552-563.	6.2	45
213	Biallelic mutations in the homeodomain of NKX6-2 underlie a severe hypomyelinating leukodystrophy. Brain, 2017, 140, 2550-2556.	7.6	18
214	International Workshop:. Neuromuscular Disorders, 2017, 27, 1126-1137.	0.6	58
215	<i>UFM1</i> founder mutation in the Roma population causes recessive variant of H-ABC. Neurology, 2017, 89, 1821-1828.	1.1	39
216	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365

#	Article	IF	CITATIONS
217	Somatic mosaicism represents an underestimated event underlying collagen 6-related disorders. European Journal of Paediatric Neurology, 2017, 21, 873-883.	1.6	4
218	A novel PMCA3 mutation in an ataxic patient with hypomorphic phosphomannomutase 2 (PMM2) heterozygote mutations: Biochemical characterization of the pump defect. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3303-3312.	3.8	17
219	Identification of novel and hotspot mutations in the channel domain of ITPR1 in two patients with Gillespie syndrome. Gene, 2017, 628, 141-145.	2.2	27
220	Revisiting mitochondrial ocular myopathies: a study from the Italian Network. Journal of Neurology, 2017, 264, 1777-1784.	3.6	32
221	The phenotypic and molecular spectrum of PEHO syndrome and PEHO-like disorders. Brain, 2017, 140, e49-e49.	7.6	33
222	Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations. Orphanet Journal of Rare Diseases, 2017, 12, 89.	2.7	39
223	Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients. Orphanet Journal of Rare Diseases, 2017, 12, 90.	2.7	49
224	Novel mutations in IBA57 are associated with leukodystrophy and variable clinical phenotypes. Journal of Neurology, 2017, 264, 102-111.	3.6	38
225	Skin and Hair Disorders. , 2017, , 341-370.		1
226	<scp>DJ</scp> â€1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of <scp>PARK7</scp> . Clinical Genetics, 2017, 92, 18-25.	2.0	34
227	Uniparental disomy of chromosome 1 unmasks recessive mutations of PPT1 in a boy with neuronal ceroid lipofuscinosis type 1. Brain and Development, 2017, 39, 182-183.	1.1	5
228	Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich's Ataxia. International Journal of Molecular Sciences, 2017, 18, 2173.	4.1	58
229	Keloids, Spontaneous or After Minor Skin Injury: Importance of Not Missing Bethlem Myopathy. Acta Dermato-Venereologica, 2017, 97, 297-298.	1.3	5
230	A mild form of adenylosuccinate lyase deficiency in absence of typical brain MRI features diagnosed by whole exome sequencing. Italian Journal of Pediatrics, 2017, 43, 65.	2.6	9
231	Congenital myopathies: clinical phenotypes and new diagnostic tools. Italian Journal of Pediatrics, 2017, 43, 101.	2.6	80
232	The Potential of iPSCs for the Treatment of Premature Aging Disorders. International Journal of Molecular Sciences, 2017, 18, 2350.	4.1	9
233	Aged induced pluripotent stem cell (iPSCs) as a new cellular model for studying premature aging. Aging, 2017, 9, 1453-1469.	3.1	27
234	Senescence-associated ultrastructural features of long-term cultures of induced pluripotent stem cells (iPSCs). Aging, 2017, 9, 2209-2222.	3.1	11

#	Article	IF	CITATIONS
235	Identifying the dynamics of actin and tubulin polymerization in iPSCs and in iPSC-derived neurons. Oncotarget, 2017, 8, 111096-111109.	1.8	11
236	The cytoskeletal arrangements necessary to neurogenesis. Oncotarget, 2016, 7, 19414-19429.	1.8	44
237	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	2.5	32
238	Functional and Gait Assessment in Children and Adolescents Affected by Friedreich's Ataxia: A One-Year Longitudinal Study. PLoS ONE, 2016, 11, e0162463.	2.5	21
239	<i><scp>PCDH</scp>19</i> â€related epilepsy in two mosaic male patients. Epilepsia, 2016, 57, e51-5.	5.1	57
240	PCDH19-related epilepsy and Dravet Syndrome: Face-off between two early-onset epilepsies with fever sensitivity. Epilepsy Research, 2016, 125, 32-36.	1.6	28
241	MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases, 2016, 11, 91.	2.7	70
242	Novel Dominant Mutation in BIN1 Gene Causing Mild Centronuclear Myopathy Revealed by Myalgias and CK Elevation. Journal of Neuromuscular Diseases, 2016, 3, 111-114.	2.6	6
243	New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients. Journal of Molecular Neuroscience, 2016, 59, 351-359.	2.3	17
244	A new multiplex method for the diagnosis of peroxisomal disorders allowing simultaneous determination of plasma very-long-chain fatty acids, phytanic, pristanic, docosahexaenoic and bile acids by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Clinica Chimica Acta, 2016, 458, 159-164.	1.1	6
245	Clinical, neuroradiological and molecular characterization of cerebellar dysplasia with cysts (Poretti–Boltshauser syndrome). European Journal of Human Genetics, 2016, 24, 1262-1267.	2.8	43
246	Deep RNA profiling identified clock and molecular clock genes as pathophysiological signatures in collagen VI myopathy. Journal of Cell Science, 2016, 129, 1671-84.	2.0	16
247	Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?. Neuromuscular Disorders, 2016, 26, 261-263.	0.6	3
248	Congenital-onset spastic paraplegia in a patient with TUBB4A mutation and mild hypomyelination. Journal of the Neurological Sciences, 2016, 368, 145-146.	0.6	8
249	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.6	144
250	Start codon mutation of GYG1 causing late-onset polyglucosan body myopathy with nemaline rods. Journal of Neurology, 2016, 263, 2133-2135.	3.6	17
251	Biallelic Mutations in TBCD, Encoding the Tubulin Folding Cofactor D, Perturb Microtubule Dynamics and Cause Early-Onset Encephalopathy. American Journal of Human Genetics, 2016, 99, 962-973.	6.2	66
252	TBCE Mutations Cause Early-Onset Progressive Encephalopathy with Distal Spinal Muscular Atrophy. American Journal of Human Genetics, 2016, 99, 974-983.	6.2	49

#	Article	IF	CITATIONS
253	A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. Cardiovascular Pathology, 2016, 25, 423-431.	1.6	34
254	Cognitive, adaptive, and behavioral features in Joubert syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 3115-3124.	1.2	22
255	Immune-mediated rippling muscle disease and myasthenia gravis. Journal of Neuroimmunology, 2016, 299, 59-61.	2.3	10
256	Childhood-onset ATP1A3-related conditions: Report of two new cases of phenotypic spectrum. Parkinsonism and Related Disorders, 2016, 30, 81-82.	2.2	18
257	Autophagy regulates satellite cell ability to regenerate normal and dystrophic muscles. Cell Death and Differentiation, 2016, 23, 1839-1849.	11.2	102
258	Frataxin silencing alters microtubule stability in motor neurons: implications for Friedreich's ataxia. Human Molecular Genetics, 2016, 25, 4288-4301.	2.9	27
259	Rho Kinase Inhibition Is Essential During In Vitro Neurogenesis and Promotes Phenotypic Rescue of Human Induced Pluripotent Stem Cell-Derived Neurons With Oligophrenin-1 Loss of Function. Stem Cells Translational Medicine, 2016, 5, 860-869.	3.3	17
260	Cytoskeletal dynamics during in vitro neurogenesis of induced pluripotent stem cells (iPSCs). Molecular and Cellular Neurosciences, 2016, 77, 113-124.	2.2	9
261	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.1	92
262	Dolichol-phosphate mannose synthase depletion in zebrafish leads to dystrophic muscle with hypoglycosylated $\hat{l}_{\pm}$ -dystroglycan. Biochemical and Biophysical Research Communications, 2016, 477, 137-143.	2.1	17
263	Response to: Mitochondrial neuropathy affects peripheral and cranial nerves and is primary or secondary or both. Neuromuscular Disorders, 2016, 26, 549.	0.6	0
264	<i>LYRM7</i> mutations cause a multifocal cavitating leukoencephalopathy with distinct MRI appearance. Brain, 2016, 139, 782-794.	7.6	51
265	High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. Experimental and Molecular Pathology, 2016, 100, 199-206.	2.1	7
266	TUBB4A-related hypomyelinating leukodystrophy: New insights from a series of 12 patients. European Journal of Paediatric Neurology, 2016, 20, 323-330.	1.6	24
267	Novel findings associated with MTM1 suggest a higher number of female symptomatic carriers. Neuromuscular Disorders, 2016, 26, 292-299.	0.6	25
268	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 regulates epidermal growth factor receptor signaling in astrocytes. Human Molecular Genetics, 2016, 25, 1543-1558.	2.9	32
269	Disease-Causing SDHAF1 Mutations Impair Transfer of Fe-S Clusters to SDHB. Cell Metabolism, 2016, 23, 292-302.	16.2	89
270	Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia. Leukemia and Lymphoma, 2016, 57, 2189-2191.	1.3	9

#	Article	IF	CITATIONS
271	"Mitochondrial neuropathiesâ€. A survey from the large cohort of the Italian Network. Neuromuscular Disorders, 2016, 26, 272-276.	0.6	37
272	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2016, 26, 126-131.	0.6	142
273	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
274	Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations. Neurogenetics, 2016, 17, 65-70.	1.4	29
275	Succinateâ€CoA ligase deficiency due to mutations in <i>SUCLA2</i> and <i>SUCLG1</i> : phenotype and genotype correlations in 71 patients. Journal of Inherited Metabolic Disease, 2016, 39, 243-252.	3.6	79
276	A novel AIFM1 mutation expands the phenotype to an infantile motor neuron disease. European Journal of Human Genetics, 2016, 24, 463-466.	2.8	51
277	Towards Understanding Human Similarity Perception in the Analysis of Large Sets of Scatter Plots. , 2016, , .		43
278	Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2016, 11, e0160195.	2.5	43
279	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2015, 25, S313.	0.6	1
280	Altered <i>PLP1 </i> splicing causes hypomyelination of early myelinating structures. Annals of Clinical and Translational Neurology, 2015, 2, 648-661.	3.7	27
281	Mutation of <i><scp>CHRNA</scp>2</i> in a family with benign familial infantile seizures: Potential role of nicotinic acetylcholine receptor in various phenotypes of epilepsy. Epilepsia, 2015, 56, e53-7.	5.1	19
282	Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in <i><scp>ASAH</scp>1</i> <. Epilepsia, 2015, 56, 692-698.	5.1	33
283	Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children. Journal of Neuromuscular Diseases, 2015, 2, 453-462.	2.6	17
284	Robotic and clinical evaluation of upper limb motor performance in patients with Friedreich's Ataxia: an observational study. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 41.	4.6	42
285	A Novel Mutation in <i>RPL10</i> (Ribosomal Protein L10) Causes X-Linked Intellectual Disability, Cerebellar Hypoplasia, and Spondylo-Epiphyseal Dysplasia. Human Mutation, 2015, 36, 1155-1158.	2.5	28
286	Old measures and new scores in spinal muscular atrophy patients. Muscle and Nerve, 2015, 52, 435-437.	2.2	6
287	Functional genome-wide siRNA screen identifies KIAA0586 as mutated in Joubert syndrome. ELife, 2015, 4, e06602.	6.0	64
288	Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. European Journal of Paediatric Neurology, 2015, 19, 497-503.	1.6	56

#	Article	IF	Citations
289	â€~Behr syndrome' with OPA1 compound heterozygote mutations. Brain, 2015, 138, e321-e321.	7.6	50
290	Longitudinal follow up of a boy affected by Pol III-related leukodystrophy: a detailed phenotype description. BMC Medical Genetics, $2015, 16, 53$ .	2.1	5
291	Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1. Neuromuscular Disorders, 2015, 25, 898-903.	0.6	13
292	Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 14-18.	0.6	34
293	COQ4 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10 Deficiency. American Journal of Human Genetics, 2015, 96, 309-317.	6.2	86
294	Prevalence of congenital muscular dystrophy in Italy. Neurology, 2015, 84, 904-911.	1.1	75
295	TMEM70 deficiency: longâ€term outcome of 48 patients. Journal of Inherited Metabolic Disease, 2015, 38, 417-426.	3.6	51
296	Oral-facial-digital syndrome type VI: is C5orf42 really the major gene?. Human Genetics, 2015, 134, 123-126.	3.8	30
297	Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 2015, 25, 749-753.	0.6	41
298	Rho-kinase signaling controls nucleocytoplasmic shuttling of class IIa Histone Deacetylase (HDAC7) and transcriptional activation of orphan nuclear receptor NR4A1. Biochemical and Biophysical Research Communications, 2015, 459, 179-183.	2.1	5
299	Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs. Journal of the Neurological Sciences, 2015, 356, 65-71.	0.6	27
300	Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care?. Neuropediatrics, 2015, 46, 033-036.	0.6	9
301	Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMedicine, 2015, 2, 285-293.	6.1	63
302	Congenital myopathies. Neurology, 2015, 84, 15-16.	1.1	0
303	Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet Journal of Rare Diseases, 2015, 10, 22.	2.7	54
304	The hyperornithinemia–hyperammonemia-homocitrullinuria syndrome. Orphanet Journal of Rare Diseases, 2015, 10, 29.	2.7	65
305	Familial periventricular nodular heterotopia, epilepsy and Melnick–Needles Syndrome caused by a singleFLNAmutation with combined gain-of-function and loss-of-function effects. Journal of Medical Genetics, 2015, 52, 405-412.	3.2	15
306	Muscle imaging in fibrodysplasia ossificans progressiva: The neurologist's perspective. Neuromuscular Disorders, 2015, 25, 672-673.	0.6	1

#	Article	IF	Citations
307	Centronuclear myopathies: genotype–phenotype correlation and frequency of defined genetic forms in an Italian cohort. Journal of Neurology, 2015, 262, 1728-1740.	3.6	51
308	Redefining phenotypes associated with mitochondrial DNA single deletion. Journal of Neurology, 2015, 262, 1301-1309.	3.6	68
309	Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. Neurology, 2015, 85, 1886-1893.	1.1	39
310	SSADH deficiency in an adult. Neurology, 2015, 85, 842-843.	1.1	2
311	POPDC1S201F causes muscular dystrophy and arrhythmia by affecting protein trafficking. Journal of Clinical Investigation, 2015, 126, 239-253.	8.2	85
312	Characterizing PCDH19 in human induced pluripotent stem cells (iPSCs) and iPSC-derived developing neurons: emerging role of a protein involved in controlling polarity during neurogenesis. Oncotarget, 2015, 6, 26804-26813.	1.8	30
313	Mitochondria fingerprint longevity in iPSCs. Oncotarget, 2015, 6, 5475-5476.	1.8	0
314	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	2.5	98
315	Oligophrenin-1 (OPHN1), a Gene Involved in X-Linked Intellectual Disability, Undergoes RNA Editing and Alternative Splicing during Human Brain Development. PLoS ONE, 2014, 9, e91351.	2.5	14
316	Mutations in GTPBP3 Cause a Mitochondrial Translation Defect Associated with Hypertrophic Cardiomyopathy, Lactic Acidosis, and Encephalopathy. American Journal of Human Genetics, 2014, 95, 708-720.	6.2	123
317	<i>LMNA</i> -associated myopathies. Neurology, 2014, 83, 1634-1644.	1.1	57
318	Frataxin Silencing Inactivates Mitochondrial Complex I in NSC34 Motoneuronal Cells and Alters Glutathione Homeostasis. International Journal of Molecular Sciences, 2014, 15, 5789-5806.	4.1	22
319	Christianson Syndrome: Spectrum of Neuroimaging Findings. Neuropediatrics, 2014, 45, 247-251.	0.6	22
320	Activating <i>PIK3CA</i> somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity. American Journal of Medical Genetics, Part A, 2014, 164, 2365-2369.	1.2	16
321	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	2.2	357
322	Affinity proteomics within rare diseases: a <scp>BIO</scp> â€ <scp>NMD</scp> study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine, 2014, 6, 918-936.	6.9	105
323	Hypomyelinating leukodystrophies: Translational research progress and prospects. Annals of Neurology, 2014, 76, 5-19.	5.3	132
324	Mutations in APOPT1, Encoding a Mitochondrial Protein, Cause Cavitating Leukoencephalopathy with Cytochrome c Oxidase Deficiency. American Journal of Human Genetics, 2014, 95, 315-325.	6.2	64

#	Article	IF	Citations
325	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	2.5	65
326	Ataxia, Intellectual Disability, and Ocular Apraxia with Cerebellar Cysts: A New Disease?. Cerebellum, 2014, 13, 79-88.	2.5	50
327	Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 201-206.	0.6	83
328	In vitro neurogenesis: development and functional implications of iPSC technology. Cellular and Molecular Life Sciences, 2014, 71, 1623-1639.	5.4	39
329	Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations. Neurogenetics, 2014, 15, 41-48.	1.4	22
330	Defects of RNA metabolism in the pathogenesis of spinal muscular atrophy. Neurology, 2014, 82, 1298-1299.	1.1	3
331	Childhood onset tubular aggregate myopathy associated with de novo STIM1 mutations. Journal of Neurology, 2014, 261, 870-876.	3.6	56
332	Glutathione metabolism in cobalamin deficiency type C (cblC). Journal of Inherited Metabolic Disease, 2014, 37, 125-129.	3.6	46
333	Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscular Disorders, 2014, 24, 347-352.	0.6	44
334	The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender?. Journal of Neurology, 2014, 261, 504-510.	3.6	119
335	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in <i>TPM2</i> and <i>TPM3</i> Causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	2.5	92
336	Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon-like effect of vitamin B2. Mitochondrion, 2014, 18, 49-57.	3.4	39
337	Diffusion tensor imaging in <i>SPG11</i> - and <i>SPG4</i> -linked hereditary spastic paraplegia. International Journal of Neuroscience, 2014, 124, 261-270.	1.6	17
338	A new simple and rapid LC–ESI-MS/MS method for quantification of plasma oxysterols as dimethylaminobutyrate esters. Its successful use for the diagnosis of Niemann–Pick type C disease. Clinica Chimica Acta, 2014, 437, 93-100.	1.1	62
339	INFUSE: Interactive Feature Selection for Predictive Modeling of High Dimensional Data. IEEE Transactions on Visualization and Computer Graphics, 2014, 20, 1614-1623.	4.4	129
340	Mitochondrial dysfunction in central nervous system white matter disorders. Glia, 2014, 62, 1878-1894.	4.9	52
341	Effects of levosimendan on mitochondrial function in patients withÂseptic shock: A randomized trial. Biochimie, 2014, 102, 166-173.	2.6	41
342	A novel mutation in the endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). Epilepsy Research, 2014, 108, 811-815.	1.6	40

#	Article	IF	Citations
343	Approach to the diagnosis of congenital myopathies. Neuromuscular Disorders, 2014, 24, 97-116.	0.6	239
344	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 modulates endosomal pH and protein trafficking in astrocytes: Relevance to MLC disease pathogenesis. Neurobiology of Disease, 2014, 66, 1-18.	4.4	20
345	Diagnostic approach to the congenital muscular dystrophies. Neuromuscular Disorders, 2014, 24, 289-311.	0.6	275
346	Myoclonus in mitochondrial disorders. Movement Disorders, 2014, 29, 722-728.	3.9	33
347	Persistent pulmonary arterial hypertension in the newborn (PPHN): A frequent manifestation of TMEM70 defective patients. Molecular Genetics and Metabolism, 2014, 111, 353-359.	1.1	31
348	Muscle magnetic resonance imaging and histopathology in <i>ACTA1â€</i> related congenital nemaline myopathy. Muscle and Nerve, 2014, 50, 1011-1016.	2.2	15
349	Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. Journal of Clinical Investigation, 2014, 124, 4693-4708.	8.2	153
350	The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys. PLOS Currents, 2014, 6, .	1.4	24
351	Aged iPSCs display an uncommon mitochondrial appearance and fail to undergo in vitro neurogenesis. Aging, 2014, 6, 1094-1108.	3.1	23
352	Dandy-Walker malformation and Wisconsin syndrome: novel cases add further insight into the genotype-phenotype correlations of 3q23q25 deletions. Orphanet Journal of Rare Diseases, 2013, 8, 75.	2.7	19
353	New clinical and molecular insights on Barth syndrome. Orphanet Journal of Rare Diseases, 2013, 8, 27.	2.7	35
354	Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet Journal of Rare Diseases, 2013, 8, 19.	2.7	42
355	Astrocytes: Emerging stars in leukodystrophy pathogenesis. Translational Neuroscience, 2013, 4, 144-164.	1.4	48
356	Joubert syndrome and related disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1879-1888.	1.8	75
357	Characterization of a rare case of Ullrich congenital muscular dystrophy due to truncating mutations within the COL6A1 gene C-Terminal domain: a case report. BMC Medical Genetics, 2013, 14, 59.	2.1	9
358	Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study. Neuromuscular Disorders, 2013, 23, 624-628.	0.6	41
359	Merosin deficient congenital muscular dystrophy: Clinical, neuroimaging and immunohistochemical study of 8 Egyptian pediatric patients. Journal of Genetic Engineering and Biotechnology, 2013, 11, 61-68.	3.3	0
360	Mutations in KLHL40 Are a Frequent Cause of Severe Autosomal-Recessive Nemaline Myopathy. American Journal of Human Genetics, 2013, 93, 6-18.	6.2	186

#	Article	IF	CITATIONS
361	Metabolic neuropathies and myopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1437-1455.	1.8	23
362	Exome sequencing in a family with intellectual disability, early onset spasticity, and cerebellar atrophy detects a novel mutation in EXOSC3. Neurogenetics, 2013, 14, 247-250.	1.4	34
363	Somatic mosaicism in TPM2-related myopathy with nemaline rods and cap structures. Acta Neuropathologica, 2013, 125, 169-171.	7.7	15
364	Pontocerebellar hypoplasia type 6 caused by mutations in <i>RARS2</i> : definition of the clinical spectrum and molecular findings in five patients. Journal of Inherited Metabolic Disease, 2013, 36, 43-53.	3.6	70
365	Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of $\hat{l}$ ±-Dystroglycan. American Journal of Human Genetics, 2013, 93, 29-41.	6.2	197
366	PRRT2 is mutated in familial and non-familial benign infantile seizures. European Journal of Paediatric Neurology, 2013, 17, 77-81.	1.6	22
367	Glutathione: A redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. Molecular Genetics and Metabolism, 2013, 109, 208-214.	1.1	49
368	Centronuclear myopathy related to dynamin 2 mutations: Clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscular Disorders, 2013, 23, 229-238.	0.6	53
369	Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 2013, 109, 366-370.	1.1	39
370	A new de novo missense mutation in MYH2 expands clinical and genetic findings in hereditary myosin myopathies. Neuromuscular Disorders, 2013, 23, 437-440.	0.6	17
371	Duchenne muscular dystrophy and epilepsy. Neuromuscular Disorders, 2013, 23, 313-315.	0.6	60
372	PRRT2 mutation causes paroxysmal kinesigenic dyskinesia and hemiplegic migraine in monozygotic twins. European Journal of Paediatric Neurology, 2013, 17, 254-258.	1.6	19
373	Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2013, 23, 451-455.	0.6	63
374	Efficacy of Miglustat in Niemann–Pick C disease: A single centre experience. Molecular Genetics and Metabolism, 2013, 110, 329-335.	1.1	17
375	Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts. Molecular and Cellular Neurosciences, 2013, 56, 307-321.	2.2	19
376	MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain, 2013, 136, 872-881.	7.6	130
377	Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF―mutation. Neurology, 2013, 80, 2049-2054.	1.1	157
378	Conventional magnetic resonance imaging and diffusion tensor imaging studies in children with novel GPR56 mutations: further delineation of a cobblestone-like phenotype. Neurogenetics, 2013, 14, 77-83.	1.4	23

#	Article	IF	CITATIONS
379	Hereditary spastic paraplegias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1899-1912.	1.8	13
380	Description of a novel TUBA1A mutation in Arg-390 associated with asymmetrical polymicrogyria and mid-hindbrain dysgenesis. European Journal of Paediatric Neurology, 2013, 17, 361-365.	1.6	23
381	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	7.6	85
382	Phenotypic spectrum and prevalence of INPP5E mutations in Joubert Syndrome and related disorders. European Journal of Human Genetics, 2013, 21, 1074-1078.	2.8	64
383	Frataxin Deficiency Leads to Reduced Expression and Impaired Translocation of NF-E2-Related Factor (Nrf2) in Cultured Motor Neurons. International Journal of Molecular Sciences, 2013, 14, 7853-7865.	4.1	75
384	Limb-girdle muscular dystrophy with $\hat{l}_{\pm}$ -dystroglycan deficiency and mutations in the <i>ISPD</i> gene. Neurology, 2013, 80, 963-965.	1.1	26
385	Evaluation of alternative glyph designs for time series data in a small multiple setting. , 2013, , .		84
386	THE 6â€minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle and Nerve, 2013, 48, 343-356.	2.2	258
387	The 6â€minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle and Nerve, 2013, 48, 357-368.	2.2	240
388	Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations. Journal of Medical Genetics, 2013, 50, 104-107.	3.2	31
389	Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. Nature Genetics, 2013, 45, 83-87.	21.4	231
390	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	2.5	99
391	Cardiomyopathy in patients with POMT1-related congenital and limb-girdle muscular dystrophy. European Journal of Human Genetics, 2012, 20, 1234-1239.	2.8	31
392	Protein glutathionylation in cellular compartments: A constitutive redox signal. Redox Report, 2012, 17, 63-71.	4.5	8
393	Megalencephalic leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the TRPV4 cation channel to activate the response of astrocytes to osmotic stress: dysregulation by pathological mutations. Human Molecular Genetics, 2012, 21, 2166-2180.	2.9	65
394	Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations. JIMD Reports, 2012, 6, 43-46.	1.5	31
395	Leukoencephalopathy with thalamus and brainstem involvement and high lactate  LTBL' caused by EARS2 mutations. Brain, 2012, 135, 1387-1394.	7.6	187
396	Importance of <i>SPP1</i> genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81

#	Article	IF	Citations
397	Empirical Studies in Information Visualization: Seven Scenarios. IEEE Transactions on Visualization and Computer Graphics, 2012, 18, 1520-1536.	4.4	429
398	DPM2â€CDC: A muscular dystrophy–dystroglycanopathy syndrome with severe epilepsy. Annals of Neurology, 2012, 72, 550-558.	5.3	121
399	Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation. Journal of Pediatrics, 2012, 161, 705-709.e1.	1.8	121
400	EPI-743 reverses the progression of the pediatric mitochondrial diseaseâ€"Genetically defined Leigh Syndrome. Molecular Genetics and Metabolism, 2012, 107, 383-388.	1.1	163
401	Consensus Statement on Standard of Care for Congenital Myopathies. Journal of Child Neurology, 2012, 27, 363-382.	1.4	147
402	Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>G) abrogated in vitro using an antisense morpholino oligonucleotide. Neurogenetics, 2012, 13, 205-214.	1.4	21
403	TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex $V$ biogenesis. Neurogenetics, 2012, 13, 375-386.	1.4	25
404	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.6	18
405	Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscular Disorders, 2012, 22, 685-689.	0.6	31
406	Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Molecular Genetics and Metabolism, 2012, 105, 463-471.	1.1	106
407	Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. Neurology, 2012, 78, 1309-1314.	1.1	40
408	Mutation of plasma membrane Ca <sup>2+</sup> ATPase isoform 3 in a family with X-linked congenital cerebellar ataxia impairs Ca <sup>2+</sup> homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14514-14519.	7.1	113
409	Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1. American Journal of Human Genetics, 2012, 91, 5-14.	6.2	250
410	Pediatric reference intervals for muscle coenzyme Q10. Biomarkers, 2012, 17, 764-766.	1.9	2
411	Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype. BMC Medical Genetics, 2012, 13, 73.	2.1	63
412	Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient. Orphanet Journal of Rare Diseases, 2012, 7, 18.	2.7	83
413	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	2.7	7
414	Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nature Genetics, 2012, 44, 1243-1248.	21.4	712

#	Article	IF	CITATIONS
415	Exon 45 Skipping Through U1-snRNA Antisense Molecules Recovers the Dys-nNOS Pathway and Muscle Differentiation in Human DMD Myoblasts. Molecular Therapy, 2012, 20, 2134-2142.	8.2	45
416	Mitochondrial DNA depletion syndrome presenting with ataxia and external ophthalmoplegia: Case report. Egyptian Journal of Medical Human Genetics, 2012, 13, 351-357.	1.0	1
417	Brown–Vialetto–van Laere and Fazio–Londe overlap syndromes: A clinical, biochemical and genetic study. Neuromuscular Disorders, 2012, 22, 1075-1082.	0.6	36
418	Stem cells in severe infantile spinal muscular atrophy. Neuromuscular Disorders, 2012, 22, 1105.	0.6	6
419	Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases. Neuromuscular Disorders, 2012, 22, S226-S229.	0.6	38
420	Somatic mosaicism of PCDH19 mutation in a family with low-penetrance EFMR. Neurogenetics, 2012, 13, 341-345.	1.4	27
421	Developmental Splicing Deregulation in Leukodystrophies Related to EIF2B Mutations. PLoS ONE, 2012, 7, e38264.	2.5	14
422	A new phenotypic variant in cleidocranial dysplasia (CCD) associated with mutation c.391C>T of the RUNX2 gene. BMJ Case Reports, 2012, 2012, bcr1220115422-bcr1220115422.	0.5	14
423	?????. Cerebrovascular Diseases, 2012, 33, 1a-1a.	1.7	7
424	Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959.	2.5	115
425	Infantile Childhood Onset of Spinocerebellar Ataxia Type 2. Cerebellum, 2012, 11, 526-530.	2.5	19
426	The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children. European Journal of Paediatric Neurology, 2012, 16, 248-256.	1.6	39
427	Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. European Journal of Paediatric Neurology, 2012, 16, 301-303.	1.6	20
428	Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology, The, 2012, 11, 443-452.	10.2	297
429	C19orf12 and FA2H Mutations Are Rare in Italian Patients With Neurodegeneration With Brain Iron Accumulation. Seminars in Pediatric Neurology, 2012, 19, 75-81.	2.0	38
430	All glutathione forms are depleted in blood of obese and type 1 diabetic children. Pediatric Diabetes, 2012, 13, 272-277.	2.9	23
431	HiTSEE KNIME: a visualization tool for hit selection and analysis in high-throughput screening experiments for the KNIME platform. BMC Bioinformatics, 2012, 13, S4.	2.6	17
432	Delineation and Diagnostic Criteria of Oral-Facial-Digital Syndrome Type VI. Orphanet Journal of Rare Diseases, 2012, 7, 4.	2.7	64

#	Article	IF	CITATIONS
433	Immunodeficiency in Vici syndrome: A heterogeneous phenotype. American Journal of Medical Genetics, Part A, 2012, 158A, 434-439.	1.2	52
434	Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease. Annals of Neurology, 2012, 71, 146-148.	5.3	15
435	Renal involvement in mitochondrial cytopathies. Pediatric Nephrology, 2012, 27, 539-550.	1.7	109
436	GM1 gangliosidosis and Morquio B disease: An update on genetic alterations and clinical findings. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 782-790.	3.8	115
437	Novel large-range mitochondrial DNA deletions and fatal multisystemic disorder with prominent hepatopathy. Biochemical and Biophysical Research Communications, 2011, 415, 300-304.	2.1	7
438	Effect of protein glutathionylation on neuronal cytoskeleton: a potential link to neurodegeneration. Neuroscience, 2011, 192, 285-294.	2.3	29
439	Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscular Disorders, 2011, 21, 194-203.	0.6	16
440	169th ENMC International Workshop Rare Structural Congenital Myopathies 6–8 November 2009, Naarden, The Netherlands. Neuromuscular Disorders, 2011, 21, 363-374.	0.6	14
441	Assessing upper limb function in nonambulant SMA patients: Development of a new module. Neuromuscular Disorders, 2011, 21, 406-412.	0.6	71
442	Cyclosporine A in Ullrich Congenital Muscular Dystrophy: Long-Term Results. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-10.	4.0	51
443	Myelinated retinal fibers in autosomal recessive spastic ataxia of Charlevoix-Saguenay. European Journal of Neurology, 2011, 18, 1187-1190.	3.3	31
444	Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations. Epilepsia, 2011, 52, 1251-1257.	5.1	74
445	Congenital Muscular Dystrophies: A Brief Review. Seminars in Pediatric Neurology, 2011, 18, 277-288.	2.0	91
446	CloudLines: Compact Display of Event Episodes in Multiple Time-Series. IEEE Transactions on Visualization and Computer Graphics, 2011, 17, 2432-2439.	4.4	127
447	Quality Metrics in High-Dimensional Data Visualization: An Overview and Systematization. IEEE Transactions on Visualization and Computer Graphics, 2011, 17, 2203-2212.	4.4	189
448	A new form of alphaâ€dystroglycanopathy associated with severe drugâ€resistant epilepsy and unusual EEG features. Epileptic Disorders, 2011, 13, 259-262.	1.3	8
449	Cardiolipin content in mitochondria from cultured skin fibroblasts harboring mutations in the mitochondrial ATP6 gene. Journal of Bioenergetics and Biomembranes, 2011, 43, 683-690.	2.3	5
450	Cerebellar hypoplasia and brainstem thinning associated with severe white matter and basal ganglia abnormalities in a child with an mtDNA deletion. Journal of Inherited Metabolic Disease, 2011, 34, 1225-1227.	3.6	3

#	Article	IF	CITATIONS
451	Progressive cavitating leukoencephalopathy associated with respiratory chain complex I deficiency and a novel mutation in NDUFS1. Neurogenetics, 2011, 12, 9-17.	1.4	43
452	FGF17, a gene involved in cerebellar development, is downregulated in a patient with Dandy–Walker malformation carrying a de novo 8p deletion. Neurogenetics, 2011, 12, 241-245.	1.4	22
453	X-linked disorders with cerebellar dysgenesis. Orphanet Journal of Rare Diseases, 2011, 6, 24.	2.7	27
454	Pontine tegmental cap dysplasia: developmental and cognitive outcome in three adolescent patients. Orphanet Journal of Rare Diseases, 2011, 6, 36.	2.7	44
455	Molecular Genetic Analysis of the PLP1 Gene in 38 Families with PLP1-related disorders: Identification and Functional Characterization of 11 Novel PLP1 Mutations. Orphanet Journal of Rare Diseases, 2011, 6, 40.	2.7	32
456	Spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2011, 6, 71.	2.7	363
457	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders, 2011, 26, 1755-1759.	3.9	125
458	Fetal akinesia in metatropic dysplasia: The combined phenotype of chondrodysplasia and neuropathy?. American Journal of Medical Genetics, Part A, 2011, 155, 2860-2864.	1.2	30
459	miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine, 2011, 3, 258-265.	6.9	242
460	Insertion of 16 amino acids in the BAR domain of the oligophrenin 1 protein causes mental retardation and cerebellar hypoplasia in an Italian family. Human Mutation, 2011, 32, E2294-E2307.	2.5	20
461	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	2.8	116
462	Functional changes in Duchenne muscular dystrophy. Neurology, 2011, 77, 250-256.	1.1	151
463	Motor Chip: A Comparative Genomic Hybridization Microarray for Copy-Number Mutations in 245 Neuromuscular Disorders. Clinical Chemistry, 2011, 57, 1584-1596.	3.2	48
464	Susceptibility of isolated myofibrils to in vitro glutathionylation: Potential relevance to muscle functions. Cytoskeleton, 2010, 67, 81-89.	2.0	20
465	GSSG-mediated Complex I defect in isolated cardiac mitochondria. International Journal of Molecular Medicine, 2010, 26, 95-9.	4.0	26
466	Novel <i>TMEM67</i> mutations and genotype-phenotype correlates in meckelin-related ciliopathies. Human Mutation, 2010, 31, n/a-n/a.	2.5	77
467	<i>RYR1</i> mutations are a common cause of congenital myopathies with central nuclei. Annals of Neurology, 2010, 68, 717-726.	5.3	230
468	Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies. BMC Medical Genetics, 2010, 11, 44.	2.1	27

#	Article	lF	CITATIONS
469	SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. European Journal of Human Genetics, 2010, 18, 52-58.	2.8	47
470	A new locus on 3p23–p25 for an autosomal-dominant limb-girdle muscular dystrophy, LGMD1H. European Journal of Human Genetics, 2010, 18, 636-641.	2.8	27
471	Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. Journal of Medical Genetics, 2010, 47, 856-858.	3 <b>.</b> 2	61
472	Pontocerebellar hypoplasia. Neurology, 2010, 75, 1459-1464.	1.1	51
473	GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain, 2010, 133, 3194-3209.	7.6	125
474	Visual quality metrics and human perception., 2010,,.		46
475	The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability. Neuromuscular Disorders, 2010, 20, 155-161.	0.6	239
476	166th ENMC International Workshop on Collagen type VI-related Myopathies, 22–24 May 2009, Naarden, The Netherlands. Neuromuscular Disorders, 2010, 20, 346-354.	0.6	29
477	Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscular Disorders, 2010, 20, 438-442.	0.6	90
478	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.6	171
479	Consensus Statement on Standard of Care for Congenital Muscular Dystrophies. Journal of Child Neurology, 2010, 25, 1559-1581.	1.4	200
480	Congenital muscular dystrophies with cognitive impairment. Neurology, 2010, 75, 898-903.	1.1	27
481	Investigating and reflecting on the integration of automatic data analysis and visualization in knowledge discovery. SIGKDD Explorations: Newsletter of the Special Interest Group (SIG) on Knowledge Discovery & Data Mining, 2010, 11, 9-18.	4.0	45
482	Visual analysis of news streams with article threads. , 2010, , .		9
483	Skin and Hair Disorders. , 2010, , 197-217.		1
484	Congenital muscular dystrophies with defective glycosylation of dystroglycan. Neurology, 2009, 72, 1802-1809.	1.1	166
485	Pathogenetic mechanisms in hereditary dysfunctions of complex I of the respiratory chain in neurological diseases. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 502-517.	1.0	33
486	Expanding <i>CEP290</i> mutational spectrum in ciliopathies. American Journal of Medical Genetics, Part A, 2009, 149A, 2173-2180.	1.2	38

#	Article	IF	Citations
487	Transcriptional behavior of DMD gene duplications in DMD/BMD males. Human Mutation, 2009, 30, E310-E319.	2.5	19
488	<i>MKS3/TMEM67</i> mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. Human Mutation, 2009, 30, E432-E442.	2.5	96
489	Screening of ARHSP-TCC patients expands the spectrum of <i>SPG11</i> mutations and includes a large scale gene deletion. Human Mutation, 2009, 30, E500-E519.	2.5	53
490	Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Human Mutation, 2009, 30, E530-E540.	2.5	59
491	Identification and characterization of novel collagen VI non-canonical splicing mutations causing ullrich congenital muscular dystrophy. Human Mutation, 2009, 30, E662-E672.	2.5	40
492	Mutations involved in Aicardi-GoutiÃ"res syndrome implicate SAMHD1 as regulator of the innate immune response. Nature Genetics, 2009, 41, 829-832.	21.4	610
493	Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nature Genetics, 2009, 41, 1032-1036.	21.4	383
494	Prenatal ultrasound and magnetic resonance imaging features in a fetus with Walker–Warburg syndrome. Ultrasound in Obstetrics and Gynecology, 2009, 33, 363-365.	1.7	25
495	Assaying ATP synthesis in cultured cells: A valuable tool for the diagnosis of patients with mitochondrial disorders. Biochemical and Biophysical Research Communications, 2009, 383, 58-62.	2.1	26
496	Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders, 2009, 19, 458-461.	0.6	171
497	Mitochondrial DNA depletion syndromes: an update. Paediatrics and Child Health (United Kingdom), 2009, 19, S32-S37.	0.4	1
498	Friedreich's ataxia: Oxidative stress and cytoskeletal abnormalities. Journal of the Neurological Sciences, 2009, 287, 111-118.	0.6	75
499	Lyonization Effects of the $t(X;16)$ Translocation on the Phenotypic Expression in a Rare Female With Menkes Disease. Pediatric Research, 2009, 65, 347-351.	2.3	22
500	CONGENITAL MUSCULAR DYSTROPHY WITH DEFECTIVE α-DYSTROGLYCAN, CEREBELLAR HYPOPLASIA, AND EPILEPSY. Neurology, 2009, 73, 1599-1601.	1.1	28
501	Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology, 2009, 72, 784-792.	1.1	110
502	Mitochondrial Encephalomyopathies and Related Syndromes: Brief Review. Endocrine Development, 2009, , 38-52.	1.3	5
503	Myosin as a potential redox-sensor: an inÂvitro study. Journal of Muscle Research and Cell Motility, 2008, 29, 119-126.	2.0	37
504	Congenital myopathies. Current Neurology and Neuroscience Reports, 2008, 8, 73-79.	4.2	26

#	Article	IF	CITATIONS
505	Cerebroretinal microangiopathy with calcifications and cysts (CRMCC). American Journal of Medical Genetics, Part A, 2008, 146A, 182-190.	1.2	87
506	Xâ€linked congenital ataxia: A new locus maps to Xq25â€q27.1. American Journal of Medical Genetics, Part A, 2008, 146A, 593-600.	1.2	12
507	De novo <i>LMNA</i> mutations cause a new form of congenital muscular dystrophy. Annals of Neurology, 2008, 64, 177-186.	5.3	255
508	Current methodological issues in the study of children with inherited neuromuscular disorders. Developmental Medicine and Child Neurology, 2008, 50, 417-421.	2.1	8
509	Protein glutathionylation increases in the liver of patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e457-64.	2.8	26
510	Genotype–phenotype correlation in five Pelizaeus–Merzbacher disease patients with <i>PLP1 </i> gene duplications. Clinical Genetics, 2008, 73, 279-287.	2.0	19
511	<i>RPGRIP1L</i> mutations are mainly associated with the cerebelloâ€renal phenotype of Joubert syndromeâ€related disorders. Clinical Genetics, 2008, 74, 164-170.	2.0	64
512	Heart transplantation in a child with LGMD2I presenting as isolated dilated cardiomyopathy. Neuromuscular Disorders, 2008, 18, 153-155.	0.6	30
513	Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscular Disorders, 2008, 18, 389-393.	0.6	92
514	POMT1 and POMT2 mutations in CMD patients: A multicentric Italian study. Neuromuscular Disorders, 2008, 18, 565-571.	0.6	38
515	Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders, 2008, 18, 536-540.	0.6	97
516	Clinical and genetic characterization of Chanarin–Dorfman syndrome. Biochemical and Biophysical Research Communications, 2008, 369, 1125-1128.	2.1	72
517	Clinical factors as predictors of survival in spinal muscular atrophy type I. Paediatrics and Child Health (United Kingdom), 2008, 18, S43-S47.	0.4	2
518	Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain, 2008, 131, 747-759.	7.6	134
519	Neurodegeneration associated with genetic defects in phospholipase A <sub>2</sub> . Neurology, 2008, 71, 1402-1409.	1.1	236
520	<i>GJA12</i> mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology, 2008, 70, 748-754.	1.1	73
521	Fibroblast autofluorescence in connective tissue disorders: a future tool for clinical and differential diagnosis?. Journal of Biomedical Optics, 2008, 13, 054025.	2.6	5
522	The Skin as a Clue for the Diagnosis of Inherited Metabolic Disorders. , 2008, , 1023-1042.		0

#	Article	IF	Citations
523	Genotype–phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology, 2007, 68, 1782-1789.	1.1	154
524	Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology, 2007, 69, 1285-1292.	1.1	120
525	Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain, 2007, 130, 2024-2036.	7.6	161
526	Revelation of a Novel <i>CLN5</i> Mutation in Early Juvenile Neuronal Ceroid Lipofuscinosis. Neuropediatrics, 2007, 38, 46-49.	0.6	41
527	Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 2007, 68, 51-55.	1.1	159
528	Characterization of recessive RYR1 mutations in core myopathies. Human Molecular Genetics, 2007, 16, 1269-1269.	2.9	1
529	Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB Journal, 2007, 21, 1210-1226.	0.5	209
530	COQ2 Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 2773-2780.	6.1	297
531	Noninvasive Ventilation in Children with Spinal Muscular Atrophy Types 1 and 2. American Journal of Physical Medicine and Rehabilitation, 2007, 86, 216-221.	1.4	46
532	Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy and Behavior, 2007, 10, 187-191.	1.7	26
533	A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus. Neuromuscular Disorders, 2007, 17, 174-179.	0.6	29
534	The Hammersmith functional score correlates with the SMN2 copy number: A multicentric study. Neuromuscular Disorders, 2007, 17, 400-403.	0.6	47
535	Ullrich myopathy phenotype with secondary ColVI defect identified by confocal imaging and electron microscopy analysis. Neuromuscular Disorders, 2007, 17, 587-596.	0.6	24
536	Neonatal-onset nemaline myopathy mimicking congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2007, 42, e19-e22.	1.6	7
537	CEP290 Mutations Are Frequently Identified in the Oculo-Renal Form of Joubert Syndrome–Related Disorders. American Journal of Human Genetics, 2007, 81, 104-113.	6.2	137
538	Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome. American Journal of Human Genetics, 2007, 81, 713-725.	6.2	375
539	SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain, 2007, 130, 862-874.	7.6	180
540	Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology, 2007, 22, 1027-1049.	1.4	754

#	Article	IF	Citations
541	Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nature Genetics, 2007, 39, 366-372.	21.4	303
542	Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren–Larsson syndrome. Journal of Human Genetics, 2007, 52, 865-870.	2.3	15
543	Somatic and germline mosaicisms in Severe Myoclonic Epilepsy of Infancy. Biochemical and Biophysical Research Communications, 2006, 341, 489-493.	2.1	102
544	Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscular Disorders, 2006, 16, 93-98.	0.6	64
545	POMT2 mutation in a patient with â€~MEB-like' phenotype. Neuromuscular Disorders, 2006, 16, 446-448.	0.6	42
546	N.P.4 03 The CHOP INTEND: A reliable motor scale for infants with neuromuscular disease. Neuromuscular Disorders, 2006, 16, 668.	0.6	5
547	Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation. Neuromuscular Disorders, 2006, 16, 548-552.	0.6	83
548	Familial Occurrence of Febrile Seizures and Epilepsy in Severe Myoclonic Epilepsy of Infancy (SMEI) Patients with SCN1A Mutations. Epilepsia, 2006, 47, 1629-1635.	5.1	48
549	Golli-MBP Copy Number Analysis by FISH, QMPSF and MAPH in 195 Patients with Hypomyelinating Leukodystrophies. Annals of Human Genetics, 2006, 70, 66-77.	0.8	16
550	Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nature Genetics, 2006, 38, 623-625.	21.4	368
551	PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nature Genetics, 2006, 38, 752-754.	21.4	497
552	Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutià res syndrome and mimic congenital viral brain infection. Nature Genetics, 2006, 38, 910-916.	21.4	592
553	Nephronophthisis type $1$ deletion syndrome with neurological symptoms: Prevalence and significance of the association. Kidney International, 2006, 70, 1342-1347.	5.2	39
554	Hypertrophic cardiomyopathy, cataract, developmental delay, lactic acidosis: A novel subtype of 3-methylglutaconic aciduria. Journal of Inherited Metabolic Disease, 2006, 29, 546-550.	3.6	30
555	"Bartter-like―phenotype in Kearns–Sayre syndrome. Pediatric Nephrology, 2006, 21, 355-360.	1.7	45
556	PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies: identification of one partial triplication and two partial deletions of PLP1. Neurogenetics, 2006, 7, 31-37.	1.4	21
557	Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranean. Neurogenetics, 2006, 7, 111-117.	1.4	43
558	Spastic paraplegia with thin corpus callosum: description of 20 new families, refinement of the SPG11 locus, candidate gene analysis and evidence of genetic heterogeneity. Neurogenetics, 2006, 7, 149-156.	1.4	43

#	Article	IF	Citations
559	The expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular dystrophy, microcephaly, and mental retardation. Human Mutation, 2006, 27, 453-459.	2.5	106
560	Vacuolating megalencephalic leukoencephalopathy with subcortical cysts: functional studies of novel variants inMLC1. Human Mutation, 2006, 27, 292-292.	2.5	25
561	Protein glutathionylation in human central nervous system: Potential role in redox regulation of neuronal defense against free radicals. Journal of Neuroscience Research, 2006, 83, 256-263.	2.9	50
562	Subcomplexes of human ATP synthase mark mitochondrial biosynthesis disorders. Annals of Neurology, 2006, 59, 265-275.	5.3	75
563	AHI1gene mutations cause specific forms of Joubert syndrome-related disorders. Annals of Neurology, 2006, 59, 527-534.	5.3	125
564	POMGnT1 Mutations in Congenital Muscular Dystrophy. Archives of Neurology, 2006, 63, 1491.	4.5	38
565	Visual quality metrics. , 2006, , .		19
566	Cardiac and Pulmonary Investigations in Bethlem Myopathy. Archives of Neurology, 2006, 63, 1617.	4.5	37
567	Characterization of recessive RYR1 mutations in core myopathies. Human Molecular Genetics, 2006, 15, 2791-2803.	2.9	103
568	Expanding the clinical spectrum of POMT1 phenotype. Neurology, 2006, 66, 1564-1567.	1.1	52
569	N-Acetylaspartylglutamate (NAAG) in Pelizaeusmerzbacher Disease. , 2006, 576, 353-359.		10
570	Sleep-Disordered Breathing in Spinal Muscular Atrophy Types 1 and 2. American Journal of Physical Medicine and Rehabilitation, 2005, 84, 666-670.	1.4	41
571	Simultaneous determination of ubiquinol and ubiquinone in skeletal muscle of pediatric patients. Analytical Biochemistry, 2005, 342, 352-355.	2.4	15
572	Clinical features, risk factors, and prognosis in transient global amnesia: a followâ€up study. European Journal of Neurology, 2005, 12, 350-356.	3.3	109
573	Acute quadriplegic myopathy in a 16-month-old child. Paediatric Anaesthesia, 2005, 15, 611-615.	1.1	O
574	De novoα-actin mutations in monozygotic twins. Clinical Genetics, 2005, 68, 91-92.	2.0	3
575	Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics, 2005, 13, 256-259.	2.8	148
576	Distinguishing the four genetic causes of jouberts syndrome-related disorders. Annals of Neurology, 2005, 57, 513-519.	<b>5.</b> 3	104

#	Article	IF	Citations
577	Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Annals of Neurology, 2005, 58, 400-410.	5.3	72
578	The natural history of Aicardi-Goutieres syndrome: Follow-up of 11 Italian patients. Neurology, 2005, 64, 1621-1624.	1.1	42
579	NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders. Journal of Medical Genetics, 2005, 42, e9-e9.	3.2	93
580	Dominant LMNA mutations can cause combined muscular dystrophy and peripheral neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1019-1021.	1.9	67
581	Phenotypic Heterogeneity in Two Unrelated Danon Patients Associated with the SameLAMPâ€2Gene Mutation. Neuropediatrics, 2005, 36, 309-313.	0.6	32
582	Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia. Neurology, 2005, 65, 1364-1369.	1.1	93
583	Cystic leukoencephalopathy without megalencephaly. Neurology, 2005, 64, 1411-1416.	1.1	29
584	Detection of common and private mutations in the COL6A1 gene of patients with Bethlem myopathy. Neurology, 2005, 64, 1931-1937.	1.1	52
585	Altered expression of the MCSP/NG2 chondroitin sulfate proteoglycan in collagen VI deficiency. Molecular and Cellular Neurosciences, 2005, 30, 408-417.	2.2	27
586	Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clinica Chimica Acta, 2005, 355, 105-111.	1.1	68
587	Two patients with †Dropped head syndrome' due to mutations in LMNA or SEPN1 genes. Neuromuscular Disorders, 2005, 15, 521-524.	0.6	61
588	Major myofibrillar changes in early onset myopathy due to de novo heterozygous missense mutation in lamin A/C gene. Neuromuscular Disorders, 2005, 15, 847-850.	0.6	20
589	Severe Abnormalities of the Pons in Two Infants with Goldenhar Syndrome. Neuropediatrics, 2004, 35, 234-238.	0.6	15
590	Incomplete penetrance in an <i>SPG3A</i> -linked family with a new mutation in the <i>atlastin</i> gene. Neurology, 2004, 62, 2138-2139.	1.1	37
591	Novel <i>SACS</i> mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type. Neurology, 2004, 62, 103-106.	1.1	66
592	Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology, 2004, 62, 262-268.	1.1	82
593	The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology, 2004, 62, 1509-1517.	1.1	152
594	Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. European Journal of Human Genetics, 2004, 12, 59-65.	2.8	235

#	Article	IF	CITATIONS
595	Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. European Journal of Human Genetics, 2004, 12, 561-566.	2.8	87
596	Respiratory Complex I in Brain Development and Genetic Disease. Neurochemical Research, 2004, 29, 547-560.	3.3	13
597	Genomic rearrangements at the IGHMBP2 gene locus in two patients with SMARD1. Human Genetics, 2004, 115, 319-326.	3.8	35
598	Prenatal diagnosis of spinal muscular atrophy with respiratory distress (SMARD1) in a twin pregnancy. Prenatal Diagnosis, 2004, 24, 839-841.	2.3	8
599	Motor function-muscle strength relationship in spinal muscular atrophy. Muscle and Nerve, 2004, 29, 548-552.	2.2	81
600	Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders, 2004, 14, 130-135.	0.6	128
601	Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology, 2004, 62, 13-16.	1.1	62
602	A mitochondrial ATPase 6 mutation is associated with Leigh syndrome in a family and affects proton flow and adenosine triphosphate output when modeled in <i>Escherichia coli</i> International Journal of Paediatrics, 2004, 93, 65-67.	1.5	8
603	Quality Metrics for 2D Scatterplot Graphics: Automatically Reducing Visual Clutter. Lecture Notes in Computer Science, 2004, , 77-89.	1.3	19
604	Alpha-actin gene mutations and polymorphisms in Italian patients with nemaline myopathy. International Journal of Molecular Medicine, 2004, 13, 805-9.	4.0	15
605	Mutation analysis in 16 patients with mtDNA depletion. Human Mutation, 2003, 21, 453-454.	2.5	69
606	Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Annals of Neurology, 2003, 53, 354-365.	5.3	55
607	Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Annals of Neurology, 2003, 54, 719-724.	5.3	141
608	Determination of glutathionyl-hemoglobin in human erythrocytes by cation-exchange high-performance liquid chromatography. Analytical Biochemistry, 2003, 312, 85-90.	2.4	28
609	Analysis of glutathione: implication in redox and detoxification. Clinica Chimica Acta, 2003, 333, 19-39.	1.1	931
610	Glutathione metabolism and antioxidant enzymes in children with down syndrome. Journal of Pediatrics, 2003, 142, 583-585.	1.8	56
611	Description, Nomenclature, and Mapping of a Novel Cerebello-Renal Syndrome with the Molar Tooth Malformation. American Journal of Human Genetics, 2003, 73, 663-670.	6.2	91
612	Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Molecular and Cellular Neurosciences, 2003, 23, 219-231.	2.2	27

#	Article	IF	CITATIONS
613	Actin Glutathionylation Increases in Fibroblasts of Patients with Friedreich's Ataxia. Journal of Biological Chemistry, 2003, 278, 42588-42595.	3.4	142
614	Role of Gabapentin in Spinal Muscular Atrophy. Journal of Child Neurology, 2003, 18, 537-541.	1.4	86
615	Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 16041-16046.	7.1	71
616	Cerebellar ataxia and coenzyme Q10 deficiency. Neurology, 2003, 60, 1206-1208.	1.1	195
617	Atypical Leigh syndrome associated with the D393N mutation in the mitochondrial ND5 subunit. Neurology, 2003, 61, 1017-1018.	1.1	29
618	Infantile ascending hereditary spastic paralysis (IAHSP). Neurology, 2003, 60, 674-682.	1.1	64
619	Genetic heterogeneity of megalencephalic leukoencephalopathy and subcortical cysts. Neurology, 2003, 61, 534-537.	1.1	68
620	Spectrum of <i>SCN1A</i> mutations in severe myoclonic epilepsy of infancy. Neurology, 2003, 60, 1961-1967.	1.1	241
621	Metabolic and Mitochondrial Ataxias. , 2003, , 231-252.		1
622	Familial severe myoclonic epilepsy of infancy: truncation of Nav1.1 and genetic heterogeneity. Epileptic Disorders, 2003, 5, 21-5.	1.3	39
622	Familial severe myoclonic epilepsy of infancy: truncation of Nav1.1 and genetic heterogeneity. Epileptic Disorders, 2003, 5, 21-5.	1.3	39 45
	Disorders, 2003, 5, 21-5.		
623	Disorders, 2003, 5, 21-5. <i>SPG3A</i> Neurology, 2002, 59, 2002-2005.  Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277,	1.1	45
623	Disorders, 2003, 5, 21-5. <i>SPG3A</i> Neurology, 2002, 59, 2002-2005.  Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277, 43557-43564.  A severe variant of childhood ataxia with central hypomyelination/vanishing white matter	3.4	45 61
623 624 625	Disorders, 2003, 5, 21-5.  (i) SPG3A /i>. Neurology, 2002, 59, 2002-2005. Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277, 43557-43564. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to <i>EIF21B5</i> mutation. Neurology, 2002, 59, 1966-1968. Fatal infantile leukodystrophy: A severe variant of CACH/VWM syndrome, allelic to chromosome 3q27.	1.1 3.4 1.1	<ul><li>45</li><li>61</li><li>67</li></ul>
623 624 625 626	Disorders, 2003, 5, 21-5.  (i) SPG3A (i). Neurology, 2002, 59, 2002-2005. Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277, 43557-43564. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to <i>EIF21B5</i> mutation. Neurology, 2002, 59, 1966-1968. Fatal infantile leukodystrophy: A severe variant of CACH/VWM syndrome, allelic to chromosome 3q27. Neurology, 2002, 58, 161-162. Antioxidant enzymes in blood of patients with Friedreich's ataxia. Archives of Disease in Childhood,	1.1 3.4 1.1	<ul><li>45</li><li>61</li><li>67</li><li>30</li></ul>
623 624 625 626	Disorders, 2003, 5, 21-5.  (i) SPG3A (i) Neurology, 2002, 59, 2002-2005. Effects on Collagen VI mRNA Stability and Microfibrillar Assembly of Three COL6A2Mutations in Two Families with Ullrich Congenital Muscular Dystrophy. Journal of Biological Chemistry, 2002, 277, 43557-43564. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to <i>EIF21B5</i> (i) mutation. Neurology, 2002, 59, 1966-1968. Fatal infantile leukodystrophy: A severe variant of CACH/VWM syndrome, allelic to chromosome 3q27. Neurology, 2002, 58, 161-162. Antioxidant enzymes in blood of patients with Friedreich's ataxia. Archives of Disease in Childhood, 2002, 86, 376-379. Determination of superoxide dismutase and glutathione peroxidase activities in blood of healthy	1.1 3.4 1.1 1.1	<ul><li>45</li><li>61</li><li>67</li><li>30</li><li>59</li></ul>

#	Article	IF	Citations
631	Collagen type VI and related disorders: Bethlem myopathy and Ullrich scleroatonic muscular dystrophy. European Journal of Paediatric Neurology, 2002, 6, 193-198.	1.6	77
632	Novel locus for autosomal dominant pure hereditary spastic paraplegia (SPG19) maps to chromosome 9q33-q34. Annals of Neurology, 2002, 51, 681-685.	5.3	44
633	Restriction in T-Cell Receptor Repertoire in a Patient Affected by Trichothiodystrophy and CD4+ Lymphopenia. Scandinavian Journal of Immunology, 2002, 56, 212-216.	2.7	3
634	Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. Journal of Neurology, 2002, 249, 200-205.	3.6	27
635	Infantile Alexander Disease: Spectrum of GFAP Mutations and Genotype-Phenotype Correlation. American Journal of Human Genetics, 2001, 69, 1134-1140.	6.2	146
636	hGFR $\hat{i}_{\pm}$ -4: a new member of the GDNF receptor family and a candidate for NBIA. Pediatric Neurology, 2001, 25, 156-161.	2.1	8
637	Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biology, 2001, 20, 475-486.	3.6	115
638	Respiratory chain defects in hereditary spastic paraplegias. Neuromuscular Disorders, 2001, 11, 565-569.	0.6	15
639	Defective dendritic cell maturation in a child with nucleotide excision repair deficiency and CD4 lymphopenia. Clinical and Experimental Immunology, 2001, 126, 511-518.	2.6	20
640	Glutathione in blood of patients with Friedreich's ataxia. European Journal of Clinical Investigation, 2001, 31, 1007-1011.	3.4	154
641	Seven novel mutations in the ORNT1 gene (SLC25A15) in patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Human Mutation, 2001, 18, 460-460.	2.5	27
642	Mutations in the gene encoding immunoglobulin $\hat{l}\frac{1}{4}$ -binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nature Genetics, 2001, 29, 75-77.	21.4	317
643	Fatal infantile leukodystrophy. Neurology, 2001, 57, 265-270.	1.1	64
644	Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7516-7521.	7.1	288
645	The T9176G mtDNA mutation severely affects ATP production and results in Leigh syndrome. Neurology, 2001, 56, 687-690.	1.1	79
646	Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology, 2001, 57, 911-914.	1.1	56
647	Ataxia in mitochondrial disorders. , 2001, , 548-561.		1
648	Ataxia, deafness, leukodystrophy: Inherited disorder of the white matter in three related patients. Neurology, 2000, 54, 2325-2328.	1.1	11

#	Article	IF	Citations
649	Novel 7-DHCR mutation in a child with Smith-Lemli-Opitz syndrome. , 2000, 91, 138-140.		13
650	X-linked congenital ataxia: A clinical and genetic study. , 2000, 92, 53-56.		38
651	Pierre Robin syndrome and Wilms tumor: An unusual association. Medical and Pediatric Oncology, 2000, 35, 83-84.	1.0	5
652	Multi-minicore disease-searching for boundaries: Phenotype analysis of 38 cases. Annals of Neurology, 2000, 48, 745-757.	<b>5.</b> 3	112
653	A novel nonsense mutation (Q509X) in three Italian late-infantile neuronal ceroid-lipofuscinosis children. Human Mutation, 2000, 15, 577-577.	2.5	9
654	Detection of mutations in the ALD gene (ABCD1) in seven Italian families: Description of four novel mutations. Human Mutation, 2000, 16, 271-271.	2.5	7
655	Oxidative abnormalities in Menkes disease. Journal of Inherited Metabolic Disease, 2000, 23, 349-351.	<b>3.</b> 6	10
656	Intrafamilial variability in hereditary spastic paraplegia associated with an <i>SPG4</i> gene mutation. Neurology, 2000, 55, 702-705.	1.1	44
657	Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome. Neuromuscular Disorders, 2000, 10, 541-547.	0.6	36
658	A novel SURF1 mutation results in Leigh syndrome with peripheral neuropathy caused by cytochrome c oxidase deficiency. Neuromuscular Disorders, 2000, 10, 450-453.	0.6	37
659	HyperCKemia as the Only Sign of McArdle's Disease in a Child. Journal of Child Neurology, 2000, 15, 137-138.	1.4	25
660	OXPHOS and mtDNA alterations in a family with spastic paraparesis. Acta Neurologica Scandinavica, 2000, 101, 255-258.	2.1	1
661	X-linked congenital ataxia: a clinical and genetic study. American Journal of Medical Genetics Part A, 2000, 92, 53-6.	2.4	10
662	Multi-minicore diseasesearching for boundaries: phenotype analysis of 38 cases. Annals of Neurology, 2000, 48, 745-57.	<b>5.</b> 3	21
663	A Novel Mutation (R271X) in the Myotubularin Gene Causes a Severe Miotubular Myopathy. Human Heredity, 1999, 49, 59-60.	0.8	8
664	Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. Neurology, 1999, 52, 810-810.	1.1	28
665	A novel de novo mutation in the triple helix of the COL6A3 gene in a two-generation Italian family affected by Bethlem myopathy. A diagnostic approach in the mutations' screening of type VI collagen. Neuromuscular Disorders, 1999, 9, 264-271.	0.6	47
666	Two novel missense mutations causing adrenoleukodystrophy in Italian patients. Molecular and Cellular Probes, 1999, 13, 179-182.	2.1	6

#	Article	IF	Citations
667	A Heterozygous Splice Site Mutation in COL6A1 Leading to an In-Frame Deletion of the $\hat{1}\pm 1$ (VI) Collagen Chain in an Italian Family Affected by Bethlem Myopathy. Biochemical and Biophysical Research Communications, 1999, 258, 802-807.	2.1	51
668	Fulminant Leigh syndrome and sudden unexpected death in a family with the T9176C mutation of the mitochondrial ATPase 6 gene. Journal of Inherited Metabolic Disease, 1998, 21, 2-8.	3.6	66
669	Familial spastic paraplegia, axonal sensory-motor polyneuropathy and bulbar amyotrophy with facial dysmorphia: New cases of Troyer-like syndrome. European Journal of Paediatric Neurology, 1998, 2, 245-254.	1.6	4
670	X-linked adrenoleukodystrophy: first report of the Italian Study Group. Italian Journal of Neurological Sciences, 1998, 19, 315-319.	0.1	7
671	Phosphomannose Isomerase Deficiency: A Carbohydrate-Deficient Glycoprotein Syndrome with Hepatic-Intestinal Presentation. American Journal of Human Genetics, 1998, 62, 1535-1539.	6.2	167
672	Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency. American Journal of Human Genetics, 1998, 63, 1609-1621.	6.2	504
673	A Novel Insertion Mutation (A169i) in the CLN1 Gene Is Associated with Infantile Neuronal Ceroid Lipofuscinosis in an Italian Patient. Biochemical and Biophysical Research Communications, 1998, 245, 519-522.	2.1	19
674	Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology, 1998, 51, 592-595.	1.1	37
675	Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement. Brain, 1997, 120, 1139-1148.	7.6	43
676	Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. ENMC International Consortium on Myotubular Myopathy. European Neuro-Muscular Center. Human Molecular Genetics, 1997, 6, 1505-1511.	2.9	113
677	The inv dup(15) syndrome. Neurology, 1997, 48, 1081-1086.	1.1	97
678	New familial mitochondrial encephalopathy with macrocephaly, cardiomyopathy, and complex I deficiency. Annals of Neurology, 1997, 42, 661-665.	5.3	14
679	Spinal muscular atrophies: recent insights and impact on molecular diagnosis. Journal of Molecular Medicine, 1996, 74, 555-562.	3.9	22
680	Hypoparathyroidism in mitochondrial trifunctional protein deficiency. Journal of Pediatrics, 1996, 129, 159-162.	1.8	62
681	Respiratory-chain and pyruvate metabolism defects: Italian collaborative survey on 72 patients. Journal of Inherited Metabolic Disease, 1996, 19, 143-148.	3.6	7
682	X-linked neurodegenerative syndrome with congenital ataxia, late-onset progressive myoclonic encephalopathy and selective macular degeneration, linked to Xp22.33-pter., 1996, 64, 69-72.		7
683	Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13. Nature Genetics, 1996, 14, 479-481.	21.4	158
684	Presymptomatic diagnosis of spinal muscular atrophy (SMA) III confirmed by deletion analysis of the survival motor neuron gene. American Journal of Medical Genetics Part A, 1995, 59, 101-102.	2.4	9

#	Article	IF	CITATIONS
685	Remission in dihydroxyphenylalanine-responsive dystonia. Movement Disorders, 1995, 10, 223-223.	3.9	8
686	Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 638-639.	1.9	36
687	High dose immunoglobulin IV treatment in adrenoleukodystrophy Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 69-71.	1.9	35
688	Bilateral, Reversible, Selective Thalamic Involvement Demonstrated by Brain MR and Acute Severe Neurological Dysfunction with Favorable Outcome*. Neuropediatrics, 1994, 25, 44-47.	0.6	30
689	Autosomal recessive hypermyelinating neuropathy. Acta Neuropathologica, 1994, 87, 337-342.	7.7	17
690	Reducing body myopathy and desmin storage in skeletal muscle: morphological and biochemical findings. Acta Neuropathologica, 1994, 87, 106-112.	7.7	29
691	A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. Journal of Pediatrics, 1994, 124, 79-86.	1.8	<b>7</b> 3
692	Reducing body myopathy and desmin storage in skeletal muscle: morphological and biochemical findings. Acta Neuropathologica, 1994, 87, 106-112.	7.7	4
693	Presymptomatic diagnosis of SMA III by genotype analysis. American Journal of Medical Genetics Part A, 1993, 45, 408-411.	2.4	7
694	Myopathy and hypertrophic cardiomyopathy with selective lysis of thick filaments. Virchows Archiv A, Pathological Anatomy and Histopathology, 1993, 422, 327-331.	1.4	8
695	Manifesting heterozygotes in McArdle's disease: clinical, morphological and biochemical studies in a family. Journal of the Neurological Sciences, 1993, 115, 91-94.	0.6	24
696	Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy. Neurology, 1993, 43, 2342-2342.	1.1	79
697	Bilateral striatal necrosis, dystonia and optic atrophy in two siblings Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 16-19.	1.9	21
698	Fatal infantile liver failure associated with mitochondrial DNA depletion. Journal of Pediatrics, 1992, 121, 896-901.	1.8	123
699	Epilepsia partialis continua and neuronal migration anomalies. Brain and Development, 1992, 14, 323-328.	1.1	33
700	Peripheral neuropathy with giant axons and cardiomyopathy associated with desmin type intermediate filaments in skeletal muscle. Journal of the Neurological Sciences, 1992, 109, 1-10.	0.6	60
701	Giant axonal neuropathy: report on a case with focal fiber loss. Acta Neuropathologica, 1992, 83, 543-546.	7.7	20
702	Biopsy diagnosis of a case of adult onset orthochromatic leukodystrophy. Clinical and brain biopsy findings. Italian Journal of Neurological Sciences, 1992, 13, 787-792.	0.1	8

#	Article	IF	CITATIONS
703	Peripheral sensory-motor polyneuropathy, pigmentary retinopathy, and fatal cardiomyopathy in long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency. European Journal of Pediatrics, 1992, 151, 121-126.	2.7	57
704	Congenital X-linked ataxia, progressive myoclonic encephalopathy, macular degeneration and recurrent infections. American Journal of Medical Genetics Part A, 1992, 43, 443-451.	2.4	16
705	Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Journal of Pediatrics, 1991, 118, 744-746.	1.8	74
706	New clinical phenotype of branched-chain acyl-CoA oxidation defect. Lancet, The, 1991, 338, 1522-1523.	13.7	69
707	Experience on Therapy of Adrenoleukodystrophy and Adrenomyeloneuropathy. Developmental Neuroscience, 1991, 13, 274-279.	2.0	58
708	Neuromyopathy and restrictive cardiomyopathy with accumulation of intermediate filaments: a clinical, morphological and biochemical study. Acta Neuropathologica, 1991, 81, 632-640.	7.7	51
709	Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA. Neurology, 1991, 41, 1053-1053.	1.1	120
710	A new therapeutic approach for X-linked adrenoleukodystrophy. European Journal of Pediatrics, 1990, 149, 595-596.	2.7	2
711	Cardiomyopathy and multicore myopathy with accumulation of intermediate filaments. European Journal of Pediatrics, 1990, 149, 856-858.	2.7	43
712	Involvement of respiratory muscles in cytoplasmic body myopathy â€" A pathological studyâ€". Brain and Development, 1990, 12, 798-806.	1.1	27
713	Impaired Skin Fibroblast Carnitine Uptake in Primary Systemic Carnitine Deficiency Manifested by Childhood Carnitine-Responsive Cardiomyopathy. Pediatric Research, 1990, 28, 247-255.	2.3	179
714	Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: A variant of infantile spinal muscular atrophy. American Journal of Medical Genetics Part A, 1989, 33, 328-335.	2.4	56
715	An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature, 1989, 339, 309-311.	27.8	640
716	Analysis of mutagenic activity in human urine after concentration on different resins and high-performance liquid chromatography. Toxicology Letters, 1989, 45, 241-249.	0.8	3
717	Hemimegalencephaly and Intractable Epilepsy: Benefits of Hemispherectomy. Epilepsia, 1989, 30, 833-843.	5.1	139
718	Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. American Journal of Medical Genetics Part A, 1988, 29, 1-8.	2.4	96
719	Late onset scleroatonic familial myopathy (Ullrich disease): A study of two sibs. American Journal of Medical Genetics Part A, 1988, 31, 933-942.	2.4	4
720	Carnitine in lactic acidosis. Journal of Pediatrics, 1988, 112, 678.	1.8	1

#	Article	IF	CITATIONS
721	Myotonic dystrophy and chromosome translocation segregating in the same family. Journal of Neurogenetics, 1987, 4, 47-56.	1.4	2
722	The CFC syndromeâ€"report of the first two cases outside the United States. American Journal of Medical Genetics Part A, 1987, 27, 767-771.	2.4	41
723	The spectrum of the so-called rigid spine syndrome: nosological considerations and report of three female cases. Journal of Neurology, 1986, 233, 248-253.	3.6	33
724	Benign congenital hypotonia with uniform type 1 fibers and aspecific ultrastructural changes in the muscle: a case with esophagus involvement. Italian Journal of Neurological Sciences, 1985, 6, 317-321.	0.1	2
725	Sacral evoked reflex in children. Neurourology and Urodynamics, 1985, 4, 149-150.	1.5	O
726	Dystrophic myopathies of early childhood onset (congenital muscular dystrophies)., 0,, 257-281.		0
727	A clinical and epidemiological prevalence study on Friedreich's Ataxia in Latium, Italy Neuroepidemiology, 0, , .	2.3	O